Compositions and methods for treating post-traumatic stress disorder

Abstract

Provided herein are methods and compositions for treating, ameliorating, or preventing post-traumatic stress disorder (PTSD). The therapeutic methods and compositions described herein include the use of at least one α2A-adrenergic receptor agonist and at least one psychedelic agent to treat, ameliorate, or prevent PTSD.

Description

[0001] Atorney Docket No. 047162-7542WOl(02749)

[0002] Compositions and Methods for Treating Post-Traumatic Stress Disorder

[0003] CROSS-REFERENCE

[0004] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 713,925, filed October 30, 2024, which is incorporated herein byreference in its entirety.

[0005] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0006] This invention was made with government support under MH122733 awarded by National Institutes of Health. The government has certain rights in the invention.

[0007] BACKGROUND

[0008] MDMA (3,4-methylenedioxymethamphetamine) has shown efficacy in Phase 3 clinical trials for Post-Traumatic Stress Disorder (PTSD) but has several undesirable sideeffects. such as, for example, abuse potential (addiction), cardiovascular effects, and neurotoxic effects. In contrast, psychedelic drugs enhance the structural plasticity of prefrontal cortex.

[0009] Thus, there is a pressing need to develop safe and effective therapies to treat Post- Traumatic Stress Disorder (PTSD) without negative side effects. The present disclosure solves this unmet need.

[0010] BRIEF SUMMARY OF THE INVENTION

[0011] In one aspect, a method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a subject in need thereof is provided. In certain embodiments, the method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a norepinephrine inhibitor (NEI), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the method includes administering to the subj ect a pharmaceutical composition comprising a therapeutically effective amount of an entactogen, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are formulated as a single dosage form or as separate Atorney Docket No. 047162-7542WOl(02749) dosage forms. In certain embodiments, the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0012] In another aspect, the method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof. In certain embodiments, the method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a ci2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms. In certain embodiments, the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0013] BRIEF DESCRIPTION OF THE FIGURES

[0014] The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments of the present application.

[0015] FIG. 1A depicts a fluorescent biosensor (AAV9-hSyn-GRABNE2h) was injected in the mPFC and a fiber implanted over the region. FIG. IB shows an example of individual traces of NE (norepinephrine) levels for injections of saline and MDMA. FIG. 1C shows a schematic of an automated detection setup for head twitch behavior for use with a mouse with magnetic ear tag. FIG. ID shows a schematic of a proposed non-limiting mechanism of MDMA action. Without being bound by theory', MDMA increases release of 5-HT (5- hydroxytiyptamine), which acts on 5-HT2A receptors to increase head twitches. MDMA also increases release of NE through binding to the NE transporter. Administration of reboxetine can block the NE transporter, inhibiting the release of NE from MDMA. FIG. IE shows NE levels for injections of MDMA co-administered with reboxetine (n=7) and fluoxetine (n=7). FIG. IF shows the average dF / F between 600-1000 seconds. Paired T test P=0.0173 (*), t=3.500, df=5). FIG. 1G shows head twitches over 30 minutes with reboxetine (10 mg / kg) or saline administered 1 minute before MDMA (5 mg / kg). Unpaired T test p=0.0001 (***), t=6.069, df=10. FIG. 1H shows a time course of head twitches per minute for reboxetine (10 mg / kg) or saline with MDMA (5 mg / kg). Atorney Docket No. 047162-7542WOl(02749)

[0016] FIGs. 2A-2C show aspects of the methods and compositions described herein, in accordance with various embodiments. FIG. 2A shows a schematic of a proposed nonlimiting model of action of MDMA and drug function. Without being bound by theory, it was hypothesized that NE was reducing the head twitch response through the alpha 2 noradrenergic receptor. Y ohimbine, an alpha 2 antagonist, will block NE from binding, and the number of head twitches was hypothesized to increase. FIG. 2B shows head twitches over 30 minutes with yohimbine (2 mg / kg) or distilled water administered 10 minutes before MDMA (10 mg / kg). Unpaired T test p=0.0133 (*), t=3. 166, df=8. FIG. 2C shows a time course of head twitches per minute for yohimbine (2 mg / kg) or distilled water with MDMA (10 mg / kg).

[0017] FIG. 3 A shows a schematic of a proposed non-limiting model of action of MDMA and drug function. Without being bound by theory, it was hypothesized that NE was reducing the head twitch response through the alpha 2 noradrenergic receptor. Administration of reboxetine will block NE release from MDMA, but guanfacine, an alpha 2 agonist, will bind to the alpha 2 receptor and inhibit the head twitch response in the absence of NE. FIG. 3B shows head twitches over 30 minutes with guanfacine (0. 15 mg / kg) or saline administered 30 minutes before MDMA (10 mg / kg) and reboxetine (10 mg / kg) administered 1 minute before MDMA. Unpaired T test p=0.0016 (**), t=4.283, df l 0. FIG. 3C shows a time course of head twitches per minute for guanfacine (0.15 mg / kg) or saline with reboxetine (10 mg / kg) and MDMA (10 mg / kg).

[0018] FIG. 4A shows a schematic of a proposed non-limiting model of action of psilocybin and drug function. Psilocybin is an agonist at the 5-HT2A receptor, but guanfacine, an alpha 2 agonist, will bind to the alpha 2 receptor and inhibit the head twitch response in the absence of NE. FIG. 4B shows head twitches over 30 minutes with guanfacine (0. 15 mg / kg) or saline administered 30 minutes before psilocybin (1 mg / kg). Unpaired T test p=0.0081 (**), t=3.296, df=10. FIG. 4C shows a time course of head twitches per minute for guanfacine (0.15 mg / kg) or saline with psilocybin (1 mg / kg).

[0019] FIG. 5 illustrates the finding that guanfacine does not interfere with psilocybin antidepressant response. Mice were exposed to two weeks of chronic multimodal stress to induce a depressive phenotype. Then, they were treated with either saline, psilocybin, or psilocybin preceded by guanfacine. One day later, the mice were assessed on the forced swim test, which is a standard antidepressant assay used to assess pharmacotherapies for depression. The results showed that guanfacine pre-treatment did not interfere with psilocybin’s antidepressant response. Atorney Docket No. 047162-7542WOl(02749)

[0020] FIGs. 6A-6B illustrate the finding that guanfacine blocks head twitch response (HTR) induced by differing doses of psilocybin. FIG. 6A: Total number of HTR over 30 minutes after administration of psilocybin (0.3 mg / kg, 1 mg / kg, or 3 mg / kg) with saline or 0.15 mg / kg Guanfacine pretreatment. Two-way ANOVA: dose psilocybin: F (2, 31) = 20.20, P < .0001 (****); pretreatment: F (1, 31) = 80.49, P < .0001 (***). FIG. 6B: HTR with pretreatment of 0. 15 mg / kg guanfacine as percent reduction in HTR with saline pretreatment. Relative percent suppression in psilocybin-induced HTR by guanfacine was calculated as the percentage change induced by guanfacine pre-treatment as compared with saline- pretreatment before that dose of psilocybin.

[0021] FIG. 7 illustrates the head twitch response (HTR) blocking effects of vary ing doses of guanfacine in mice treated with psilocybin (1 mg / kg). The results demonstrate that the effect is dose-dependent, occurring at a dosage which approximates ty pically used guanfacine dosages equivalent to those used in humans. In addition, the results demonstrate that guanfacine's suppression of head twitch is observed across a range of doses, and the reduction of head twitch is monotonic, in accordance of various embodiments.

[0022] FIG. 8A shows schematic representation of the experimental timeline, illustrating the Chronic Multimodal Stress (CMMS) procedure and the pre- and post-assessment phases, in accordance w ith one or more embodiments of the present disclosure. Abbreviations in the timeline include Sucrose Preference Test (SPT). Tail Suspension Test (TST). and Forced Swim Test (FST). FIG. 8B shows Sucrose Preference Test (SPT), comparing baseline, poststress, and post-treatment measures within each group, in accordance w ith one or more embodiments of the present disclosure. Individual values are represented as dots, with error bars indicating the mean ± S.E.M. Sal-Sal represents the Saline-Saline group, Sal-Psilo represents the Saline-Psilocybin group (1 mg / kg), and Guan-Psilo represents the Guanfacine- Psilocybin group (0.15 mg / kg and 1 mg / kg). FIG. 8C shows Forced Swim Test (FST) conducted 24 hours following treatment, in accordance with one or more embodiments of the present disclosure. Individual values are represented as dots, with error bars indicating the mean ± S.E.M. The same order of the groups is used as in FIG. 8B. An asterisk (*) represents p-values greater than 0.05, two asterisks (**) indicate p-values greater than 0.01, and four asterisks (****) indicate p-values less than 0.0001. (n = 19 / 20 per group).

[0023] FIG. 9 shows Open Field Test assessing locomotor activity7following guanfacine administration. Total distance traveled (cm / lh) was measured over a 60-minute period after injection, in accordance with one or more embodiments of the present disclosure. Individual values are represented as dots, with error bars indicating the mean ± S.E.M. Saline represents Atorney Docket No. 047162-7542WOl(02749) the Saline group, G 0.015 represents the Guanfacine 0.015 mg / kg group, G 0.15 represents the Guanfacine 0.15 mg / kg group, and G 0.5 represents the Guanfacine 0.5 mg / kg group. No significant differences were observed between groups (n = 6 / 7 per group).

[0024] DETAILED DESCRIPTION

[0025] Reference will now be made in detail to certain embodiments of the disclosed subject mater. While the disclosed subject mater will be described in conjunction with the enumerated claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject mater.

[0026] Throughout this document, values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a range of “about 0.1% to about 5%"’ or “about 0.1% to 5%” should be interpreted to include not just about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement “about X to Y” has the same meaning as “about X to about Y,” unless indicated otherwise. Likewise, the statement “about X, Y, or about Z” has the same meaning as “about X, about Y, or about Z,” unless indicated otherwise.

[0027] In this document, the terms “a.” “an;’ or “the” are used to include one or more than one unless the context clearly dictates otherwise. The term “or” is used to refer to a nonexclusive “or” unless otherwise indicated. The statement “at least one of A and B” or “at least one of A or B” has the same meaning as “A, B, or A and B.” In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section.

[0028] In the methods described herein, the acts can be carried out in any order, except when a temporal or operational sequence is explicitly recited. Furthermore, specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process. Atorney Docket No. 047162-7542WOl(02749)

[0029] Definitions

[0030] The term “about” as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range, and includes the exact stated value or range.

[0031] The term “substantially” as used herein refers to a majority7of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%. The term “substantially free of’ as used herein can mean having none or having a trivial amount of, such that the amount of material present does not affect the material properties of the composition including the material, such that the composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5. 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less. The term “substantially free of’ can mean having a trivial amount of, such that a composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4. 3.5, 3, 2.5, 2, 1.5, 1, 0.9. 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less, or about 0 wt%.

[0032] The term “independently selected from” as used herein refers to referenced groups being the same, different, or a mixture thereof, unless the context clearly indicates otherwise. Thus, under this definition, the phrase “X1, X2, and X3are independently selected from noble gases” would include the scenario where, for example, X1, X2, and X3are all the same, where X1, X2, and X3are all different, where X1and X2are the same but X3is different, and other analogous permutations.

[0033] Whenever the term “at least,” “no more than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “at least,” “no more than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, at least or no more than 1, 2, or 3 is at least or no more than 1, at least or no more than 2, or at least or no more than 3.

[0034] The term “room temperature” as used herein refers to a temperature of about 15 °C to 28 °C.

[0035] The term “standard temperature and pressure” as used herein refers to 20 °C and 101 kPa.

[0036] As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound described herein with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a Atorney Docket No. 047162-7542WOl(02749) patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to. intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

[0037] A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate.

[0038] In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.

[0039] As used herein, the terms "effective amount,” “pharmaceutically effective amount” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

[0040] As used herein, the term “efficacy” refers to the maximal effect (Emax) achieved within an assay.

[0041] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, z.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0042] As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compounds prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic acids or bases, organic acids or bases, solvates, hydrates, or clathrates thereof.

[0043] Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric (including sulfate and hydrogen sulfate), and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic. heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, Atorney Docket No. 047162-7542WOl(02749) ascorbic, glucuronic, maleic, malonic, saccharin, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2- hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, P-hydroxy butyric, salicylic, galactaric and galacturonic acid.

[0044] Suitable pharmaceutically acceptable base addition salts of compounds described herein include, for example, ammonium salts, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N’-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.

[0045] As used herein, the term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound described herein within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound(s) described herein, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose: starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cotonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that Atorney Docket No. 047162-7542WOl(02749) are compatible with the activity of the compound(s) described herein, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound(s) described herein. Other additional ingredients that may be included in the pharmaceutical compositions used with the methods or compounds described herein are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985. Easton, PA), which is incorporated herein by reference.

[0046] The terms “patient,” “subject,” or “individual” are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject or individual is a human.

[0047] As used herein, the term “potency” refers to the dose needed to produce half the maximal response (EDso).

[0048] A “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology, for the purpose of diminishing or eliminating those signs.

[0049] As used herein, the term "treatment” or “treating” is defined as the application or administration of a therapeutic agent, i.e., a compound or compounds as described herein (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient (e.g., for diagnosis or ex vivo applications), who has a condition contemplated herein or a symptom of a condition contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a condition contemplated herein, or the symptoms of a condition contemplated herein. Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

[0050] As used herein, “administered concurrently” means as short a time as possible within the practical physical limits of the ability of the patient taking the dosage form(s) or the practical physical abilities of a medical professional administering the dosage form(s). In some embodiments, “administered concurrently” includes simultaneous administration.

[0051] Therapeutic Compositions i. Entactogens and NEIs

[0052] Provided herein are entactogens useful within the disclosure. Provided herein are norepinephrine inhibitors (NEIs) useful within the disclosure. Atorney Docket No. 047162-7542WOl(02749)

[0053] Provided herein are therapeutic compositions comprising at least one entactogen and at least one norepinephrine inhibitor (NEI).

[0054] Suitable entactogens include, for example, MDMA (3,4- methylenedioxymethamphetamine), MDA (3,4-methylenedioxyamphetamine), MDEA (3,4- methylenedioxy-A-ethylamphetamine), MDOH (3,4-methylenedioxy-N- hydroxyamphetamine), MBDB ( 1.3 -benzodi oxolyl-A-methylbutanamine), 5-APB (1- benzofuran-5-ylpropan-2-amine), 5-MAPB (1 -(benzol uran-5-yl)- / V-methylpropan-2 -amine), 6- APB (6-(2-aminopropyl)benzofuran), 6-MAPB (l-(benzofuran-6-yl)-A-methylpropan-2- amine), methylone (3,4-methylenedioxy-N-methylcathinone), mephedrone (4- methylmethcathinone), GHB (y-hydroxybutyric acid), aMT (a-methyltryptamine), aET (a- ethyltryptamine), MDAI (5,6-methylenedioxy-2-aminoindane). and the like, including solvates, enantiomers, diastereomers, tautomers, and salts (such as pharmaceutically acceptable salts) thereof.

[0055] Suitable NEIs include, for example, atomoxetine ((7?)-A-methyl-3-phenyl-3-(o- tolyloxy)propan-l -amine), reboxetine (re / -(2R)-2-\(R)-(2- ethoxy phenoxy )(phenyl)methylj morpholine), viloxazine <(7AS')-2-| (2- ethoxyphenoxy)methyl]morpholine), Amedalin (UK-3540-1), Daledalin (UK-3557-15), Edivoxetine (LY-2216684), Esreboxetine (AXS-14; PNU-165442G), Lortalamine (LM- 1404), Nisoxetine (LY-94,939), Talopram (tasulopram) (Lu 3-010), Talsupram (Lu 5-005), Tandamine (AY-23,946), and the like, including solvates, enantiomers, diastereomers, tautomers, and salts (such as pharmaceutically acceptable salts) thereof.

[0056] The therapeutic compositions can be in separate dosage forms or in a single dosage form. A separate dosage form for the therapeutic composition described herein means that the entactogen is present in a first dosage form administrable by any of the deliver}’ methods described herein, and the NEI is present in a second dosage form administrable by any of the delivery methods described herein. A separate dosage form contains only the entactogen as the active pharmaceutical ingredient or only the NEI as the active pharmaceutical ingredient. Each of the separate dosage forms can further independently include one or more pharmaceutically acceptable carriers or excipients, as described herein. Thus, the pharmaceutically acceptable carriers or excipients in the NEI-containing dosage form can be the same or different as the pharmaceutically acceptable carriers or excipients in the entactogen-containing dosage form.

[0057] The dosage form containing the entactogen, either the single dosage form or the separate dosage form, can be formulated as a dosage form with anti-abuse features. Anti- Atorney Docket No. 047162-7542WOl(02749) abuse features can include 1) through a prodrug of the entactogen, 2) via an intractable matrix formulation technique, and 3) by antagonist incorporation into the product formulation. In certain embodiments, the anti-abuse properties can include formulation of acid addition salts of the entactogen such that the salt is insoluble in the mucosal membranes of humans, but the entactogen becomes bioavailable when the salt is subjected to the environment in the gastrointestinal tract. In certain non-limiting embodiments, a dosage form having anti-abuse features can be formulated as described in, for example. US 7,842,307, GB 2238478A. US 7,230,005, WO 2010 / 044842, WO 2013 / 003845, EP 1611880, US 7,510,726, US 7,399,488, US 2009 / 0215808, US 2010 / 0249045, WO 2010 / 105672, WO 2010 / 066034, US 10,420,729, and the like, the disclosures of which are herein incorporated by reference.

[0058] When the dosage form is a single solid dosage form, such as a tablet, the dosage form can be formulated such that the NEI is formulated to be an immediate release component and the entactogen is a delayed or sustained release component. Alternatively, when the dosage form is a single solid dosage form, such as a tablet, the dosage form can be formulated such that the entactogen is formulated to be an immediate release component and the NEI is a delayed or sustained release component. The NEI and entactogen dosage forms, either single dosage forms or separate dosage forms, can be formulated as pharmaceutical compositions containing at least pharmaceutically acceptable excipient or carrier as described herein.

[0059] In certain embodiments, the single or separate dosage form contains about 1 to about 1000 mg, or about 1 to about 500 mg, or about 1 to about 400 mg, or about 1 to about 300 mg, or about 1 to about 250 mg, or about 1 to about 200 mg, or about 1 to about 150 mg, or about 1 to about 100 mg, or about 1 to about 90 mg, or about 1 to about 80 mg, or about 1 to about 70 mg, or about 1 to about 60 mg, or about 1 to about 50 mg, or about 1 to about 40 mg, or about 1 to about 30 mg, or about 1 to about 20 mg, or about 1 to about 10 mg of the entactogen, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135. 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195. 200, 205, 210, 215,

[0060] 220, 225. 230, 235, 240. 245, 250. 255, 260, 265. 270, 275. 280, 285. 290, 295, 300. 305,

[0061] 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395,

[0062] 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485,

[0063] 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575,

[0064] 580, 585. 590, 595, 600, 605, 610. 615, 620, 625, 630, 635. 640, 645. 650, 655, 660, 665,

[0065] 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, Atorney Docket No. 047162-7542WOl(02749)

[0066] 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845,

[0067] 850, 855. 860, 865, 870, 875, 880. 885, 890, 895, 900, 905, 910, 915. 920, 925, 930, 935,

[0068] 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, or 1000 mg of the entactogen, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0069] In certain embodiments, the single or separate dosage form contains about 100, 105, 110, 115. 102, 125, 130, 135, or 150 mg of the entactogen, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 125 mg of MDMA.

[0070] In certain embodiments, the single or separate dosage form contains about 1 to about 1000 mg, or about 1 to about 500 mg, or about 1 to about 400 mg, or about 1 to about 300 mg, or about 1 to about 250 mg, or about 1 to about 200 mg, or about 1 to about 150 mg. or about 1 to about 100 mg, or about 1 to about 90 mg, or about 1 to about 80 mg, or about 1 to about 70 mg, or about 1 to about 60 mg, or about 1 to about 50 mg, or about 1 to about 40 mg, or about 1 to about 30 mg, or about 1 to about 20 mg, or about 1 to about 10 mg of the NEI, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195,

[0071] 200, 205. 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265. 270, 275, 280, 285,

[0072] 290, 295. 300, 305, 310, 315, 320. 325, 330, 335, 340, 345. 350, 355. 360, 365, 370, 375,

[0073] 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465,

[0074] 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555,

[0075] 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645,

[0076] 650, 655. 660, 665, 670, 675, 680. 685, 690, 695, 700, 705, 710, 715. 720, 725, 730, 735,

[0077] 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825,

[0078] 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915,

[0079] 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, or 1000 mg of the NEI, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0080] In certain embodiments, the single or separate dosage form contains about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 mg of the NEI, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains 8 mg of reboxetine. Atorney Docket No. 047162-7542WOl(02749)

[0081] In certain embodiments, the NEI is administered prior to administration of the entactogen. In certain embodiments, the NEI can be administered about 1, 5. 10. 15. 30, or 60 minutes before administration of the entactogen. In certain embodiments, the NEI can be administered about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours before administration of the entactogen. In certain embodiments, the NEI and the entactogen are administered concurrently, for example either as part of a single dosage form, or as part of separate dosage forms taken together at the same time.

[0082] In certain embodiments, the entactogen is MDMA.

[0083] In certain embodiments, the NEI is reboxetine. ii. Psychedelic Agents and a.2A-Adrenergic Receptor Agonists

[0084] Provided herein are psychedelic agents useful within the disclosure. Provided herein are ct2A-adrenergic receptor agonists (AARAs) useful within the disclosure.

[0085] Provided herein are therapeutic compositions comprising at least one psychedelic agent and at least one c -adrenergic receptor agonist (AARA).

[0086] Suitable psychedelic agents include, for example, psilocybin, 2C-B (4-bromo-2,5- dimethoxyphenethylamine), ketamine (racemic, / ^ketamine. or 5-ketamine), DMT (N,N- dimethyltryptamine), 5-MeO-DMT (5-methoxy-dimethytryptamine), LSA (d-lysergic acid amide), LSD (lysergic acid diethylamide), and the like, including solvates, enantiomers, diastereomers, tautomers, and salts (such as pharmaceutically acceptable salts) thereof. The psilocybin is, in certain embodiments, isolated pure psilocibin that is substantially free of any other substances found in Psilocybe mushroom species. The psilocybin can be at least 95, 96, 97, 98, 99, or 99.9% pure psilocybin.

[0087] Suitable psychedelic agents can also include, for example Psilocin, Psilocybin, Bufotenin, Baeocystin, Aeruginascin, 5-MeO-DMT, N,N-Dimethyltryptamine (DMT), 5- Bromo-DMT, N-Methyl-N-ethyltryptamine (MET), N-Methyl-N-isopropyltryptamine (MiPT), N-Methyl-N-propyltryptamine (MPT), N,N-Diethyltryptamine (DET), N-Ethyl-N- isopropyltiyptamine (EiPT), N-Methyl-N-butyltryptamine (MBT), N-PropyLN- isopropyltryptamine (PiPT), N,N-Dipropyltryptamine (DPT), N,N-Diisopropyltryptamine (DiPT), N,N-Diallyltryptamine (DALT), N,N-Dibutyltryptamine (DBT), N-Ethyltryptamine (NET), N-Methyltryptamine (NMT), Tnmelhyllryptamine (TMT), a-Methyltryptamine, a- Ethyltryptamine, a,N-DMT, a,N ,N-Trimethyltryptamine, Ethocybin. 4-HO-MET, 4-HO- DET. 4-HO-MPT, 4-HO-MiPT, 4-HO-MALT, 4-HO-DPT, 4-HO-DiPT, 4-HO-DALT, 4- HO-DBT, 4-HO-DSBT, 4-HO-aMT, 4-HO-MPMI, 4-HO-TMT, 4-HO-l,N,N-TMT, 4-HO- Atorney Docket No. 047162-7542WOl(02749)

[0088] 5-MeO-DMT, 4-AcO-DMT, 4-AcO-MET, 4-AcO-MALT, 4-AcO-DET, 4-AcO-EiPT, 4- AcO-DPT, 4-AcO-DiPT, 4-AcO-DALT, 4-MeO-DMT. 4-MeO-MiPT. 5-MeO-N MT. 5- MeO-MET, 5-MeO-MPT, 5-MeO-MiPT, 5-MeO-DET, 5-MeO-Ei PT, 5-MeO-EPT, 5- MeO-Pi PT, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-DALT, 5-MeO-aMT, 5-MeO-2,N,N- TMT, 5-MeO-7,N,N-TMT, 5-MeO-a,N-DMT, 4-F-5-MeO-DMT, 5-Me-MiPT, 5-HO-DiPT, 2-a-DMT, 4-Me-aMT. 4-Me-aET, 7-Me-aET, 4,5-DHP-AMT, 4,5 -DH P-DMT, 4.5 -MDO- DMT, 4,5-MDO-DiPT, 5,6-MDO-DiPT, 5,6-MDO-MiPT, 5-Fluoro-aMT, 6-Fluoro-aMT.

[0089] 6-Fluoro-DMT, N,N-Tetramethyl eneliy ptamine (Pyr-T), 4-HO-pyr-T, 5-MeO-pyr-T, RU- 28306 (4,a-Methylene-N,N-DMT), 0-4310 (6-Fluoro-l-Isopropyl-4-HO-DMT), CP- 132,484 (4, 5-DFIP-l -Methyltryptamine), Dimemebfe (5-MeO-BFE), 5-MeO-DiBF, Ibogaine. Voacangine. Lysergic acid diethylamide (LSD), Lysergic acid amide (LSA). Lysergic acid diamide, N1 -Methyl-lysergic acid diethylamide, 1 -Propionyl-lysergic acid diethylamide, 1-cyclopropanoyLd-lysergic acid diethylamide, 1-valeryl-D-lysergic acid diethylamide, 6-Allyl-6-nor-lysergic acid diethylamide, 6-Butyl-6-nor-lysergic acid diethylamide, 6-Ethyl-6-nor-lysergic acid diethylamide. l-Propionyl-6-Ethyl-6-nor-lysergic acid diethylamide, 6-Propyl-6-nor-lysergic acid diethylamide, 6-Cyclopropyl-6-nor-lysergic acid diethylamide, 6-nor-Lysergic acid diethylamide, Lysergic acid ethylamide, Lysergic acid a-hydroxy ethylamide, Lysergic acid 2- butyl amide, Lysergic acid 3-pentyl amide, Lysergic acid methyl ester, Lysergic acid 2,4-dimethylazetidide, Lysergic acid piperidine, N,N-Dimethyl-lysergamide, Methylisopropyllysergamide, N.N-Diallyllysergamide, N- Pyrrolidyllysergamide, N-Morpholinyllysergamide, 1 -methyl-lysergic acid butanolamide, Lysergic acid 0-propanolamide, Lysergic acid 1 -butanolamide, Mescaline, Lophophine, Isomescaline, Cyclopropylmescaline, Thioisomescaline (2 -TIM, 3-TIM, and 4-TIM), 4- Desoxymescaline, Jimscaline, Escaline, Metaescaline, Thiometaescaline (3-TME, 4-TME. and 5-TME), Trisescahne, Thiotrisescaline (3-T-TRIS and 4-T-TRIS), Symbescaline, Asymbescaline, Thiosymbescaline (3-TSB and 4-TSB), Phenescaline, Allylescaline, Methallylescaline, Proscaline, Isoproscaline, Metaproscaline, Thioproscaline, Buscaline, Thiobuscaline, a-ethylmescaline, Ariadne, Macromerine, MEPEA, TOM (2-TOM and 5- TOM), Bis-TOM, TOMSO (2-methoxy-4-methyl-5-methylsulfmylamphetamine), TOET (2- TOET and 5-TOET), BOH, BOM (13-Methoxy-mescaline), beta-D, 4-D, DME, F-2, F-22, FLEA, MDPH, MDMP, Propynyl, 2C family (2,5-dimethoxy, 4-substituted phenethylamines), 0k-2C-B, 2C-B, 2CB-2EtO, 2CB-5EtO, 2CB-diEtO, 2C-B-FLY, 2C-B- BUTTERFLY. 2C-C, 2C-D. 2CD-2E1O, 2CD-diEtO, 2CD-5EtO. 2C-E, 2C-EF, 2C-F, 2C-G (2C-G-1, 2C-G-2, 2C-G-3, 2C-G-4, 2C-G-5, 2C-G-6, and 2C-G-N), 2C-H, 2C-I, 2CI-2EtO, Atorney Docket No. 047162-7542WOl(02749)

[0090] 2C-iP, 2C-N, 2C-O, 2C-O-4, 2C-P, 2C-SE, 2C-T, 2CT-5EtO, 2C-T-2, 2CT-2-2EtO, 2CT-2- 5EtO, 2CT-2-diEtO, 2C-T-4 (2C-T-4 and T-2C-T-4), 2CT-4-2E1O. 2C-T-7, 2CT-7-2EtO, 2C-T-8, 2C-T-9, 2C-T-13, 2C-T-15, 2C-T-16, 2C-T-17, 2C-T-19, 2C-T-21, 2C-TFM, 2C- YN, BOB (I3-Methoxy-2C-B), BOD (I3-Methoxy-2C-D), BOHD (I3-Hydroxy-2C-D), HOT-2, HOT-7, HOT-17, Indane derivatives comprising 2CB-Ind, Benzocyclobutene derivatives comprising 2C-BCB (TCB-2), NBOMe derivatives comprising NBOMe- mescaline, 2C-H-NBOMe, 2C-C-NBOMe, 2CBCB-NBOMe, 2CBFly-NBOMe, 2C-B- NBOMe, 2C-I-NBOMe, 2C-TFM-NBOMe, 2C-D-NBOMe, 2C-G-NBOMe, 2C-E- NBOMe, 2C-P-NBOMe, 2C-iP-NBOMe, 2C-CN-NBOMe, 2C-N-NBOMe, 2C-T-NBOMe, 2C-T-4-NBOMe, 2C-T-7-NBOMe, and DMBMPP, NBOH derivatives comprising 2C-C- NBOH, 2C-B-NBOH, 2C-I-NBOH, and 2C-CN-NBOH, NBMD derivatives comprising 2C-I-NBMD, NBF derivatives comprising 2C-C-NBF, 2C-B-NBF, and 2C-I-NBF, 3C family (3,5-dimethoxy, 4-substituted amphetamines) comprising 3C-E, 3C-P, 3C-DFE, and 3C-BZ, DOx family (2,5-dimethoxy, 4-substituted amphetamines) comprising DOAM, DOB, Meta-DOB, Methyl-DOB, DOBU, DOC, DOEF, DOET. DOE DOM, T-DOM, DON, DOPR, SOiPR, DOT. Meta-DOT, Ortho-DOT. and DOTFM, DMCPA, DMMDA, DMMDA-2, 2,5-dimethoxy-3,4-dimethylamphetamine, 4-methyl-2,5- dimethoxymethamphetamine, 2,N-dimethyl-4,5-methylenedioxyamphetamine, Dimethoxy amphetamine (2,4-DMA. 2,5-DMA, and 3,4-DMA), Trimethoxyamphetamine (TMA-2. TMA-6). Tetramethoxyamphetamine, Br-DragonFLY, TFMFly, 2-Bromo-4,5- methylenedi oxy amphetamine, 4-Bromo-3,5-dimethoxyamphetamine, EEE, EEM, EME, EMM, EDMA, EID A, Ethyl-J, Methyl-J, Ethyl-K, Mehtyl-K. IDNNA, Iris, MDAI, MDMAI, MDAT, MDMAT, MDAL, MDBU. MDBZ, MDDM, MDIP, MDMEOET, MDMEO, MDOH. MDHOET, MDPL, MDCPK, MDPR. MED A, MEM, Mehtyl-DMA. MMDA, MMDA-2, 5-Mehtyl-MDA, MEE, MME, MPM, DiFMDA, 5-APB, 6-APB, 5- APDB, 6-APDB, 5-MAPB, 5-MAPDB, 6-MAPDB, 6-MAPB, 6-EAPB, 5-EAPB, Para- Methoxy amphetamine, Paramethoxymethamphetamine, 4-Ethylamphetamine, 3-Methoxy- 4-methylamphetamine, 4-Methylmethamphetamine, 4-Methylthioamphetamine, 4- Fluoroamphetamine, Norfenfluramine, Para-Iodoamphetamine, Para-Chloroamphetamine, Benzoxazine, Efavirenz, Substituted methylenedioxy-phenethylamines (MDxx) comprising 3,4-methylenedioxymethamphetamine (MDMA), MDA, 2,3-MDA, 5-Methyl-MDA, MMDA, MDEA, MBDB, MDAL, MDBU, MDBZ, MDDM, MDIP, MDMEOET, MDMEO, MDOH. MDHOET, MDPL, MDCPM. MDPR, BDB, MMDA-2, DiFMDA. EID A, Ethyl-K, Lophophine, Substituted amphetamines, EDMA, Para- Atorney Docket No. 047162-7542WOl(02749)

[0091] Methoxy amphetamine (PMA), Paramethoxy methamphetamine (PMMA), 4- Ethylamphetamine, 3-Methoxy-4-methylamphetamine, 4-Methylmethamphetamine, 4- Methylthioamphetamine, 4-Fluoroamphetamine, Norfenfluramine, Para-Iodoamphetamine, Para-Chloroamphetamine, Substituted cathinones, Methylone, Ethylone, Eutylone, Butylone, Penty lone, 4-Ethyl methcathinone, 3-Methylmethcathinone, Substituted benzofurans, 5-AP B, 6-AP B, 5-APDB, 6-APDB, 5-MAPB, 5-MAPDB, 6-MAPDB, 6- MAPB, 5-EAPB, 6-EAPB, 5-MBPB, MDAT, MDMAT, 6-CAT, Tetralinylaminopropane, Trifluoromethylaminoindane, Ethyltrifluoromethylaminoindane, 5-Iodo-2-aminoindane, MMAI, MDAI, MDMAI, Indanylaminopropane, Naphthylaminopropane, 4- chlorophenylisobutylamine, 4-Methylphenylisobutylamine, Ariadne, a-methyltryptamine, 5-MeO-aMT, a-ethyltyptamine, 4-Me-aET, 7-Me-aET, 5-MeO-aET, 5-MeO-MiPT, A9- THC, CBD, CBN, THCV, (C6)-CP 47,497, (C9)-CP 47,497, l-Butyl-3-(2- methoxybenzoyl)indole, 1 -Butyl-3-(4-methoxybenzoyl)indole, 1 -Pentyl-3-(2- methoxybenzoyl)indole, 2-Isopropyl-5-methyl-l-(2,6-di hydroxy-4-nonylphenyl)cyclohex- 1-ene, 4-HTMPIPO, 4-Nonylphenylboronic acid, 5Br-U R-144, 5C1-APINACA, 5C1-U R- 144, 5F-3-pyndinoylindole, 5F-AB-FUPPYCA. 5F-ADB-PINACA, 5F-ADBICA. 5F- ADB, 5F-AMB, 5F-APINACA, 5F-CUMYL-PINACA, 5F-EMB-PINACA, 5F-NNE1, 5F- PB-22, 5F-PCN, 5F-PY-PICA, 5F-PY-P INACA, 5F-SDB-006, HHC, A-796,260, A- 834,735, A-836,339, A-955,840, A-40174, A-41988, A-42574, AB-001, AB-CH FU PYCA. AB-CHMFUPPYCA, AB-CHMINACA, AB-FUBICA. AB-FUBINACA 2- fluorobenzyl isomer, AB-FUBINACA, AB-PICA, AB-PINACA, Abnormal cannabidiol, ADAMANTYL-THPINACA, ADB-CHMINACA, ADB-FUBICA, ADB-FUB INACA, ADB-PINACA, ADBICA, ADS B-FU B-187, Ajulemic acid, AM-087, AM-411, AM-630, AM-679. AM-694. AM-855, AM-883, AM-905, AM-906, AM-919, AM-926, AM-938, AM-1220, AM-1221, AM-1235, AM-1241, AM-1248, AM-1346, AM-1387, AM-1714, AM-2201, AM-2232, AM-2233, AM-2389, AM-4030, AM-4113, AM-6527, AM-6545, AM-251, AM-281, AM-404, AMB-CHMINACA, AMB-FUBINACA, AMG-1, AMG-3, AMG-36, AMG-41, APICA, APINACA, APP-FUBINACA, Arachidonoyl SEROTONIN, ACEA. ACPA, Arvaml, AZ-11713908, BAY 38-7271, BAY 59-3074, BIM-018, Biochanin A, BML-190, Nabidrox (Canbisol), Cannabicyclohexanol, Cannabipiperidiethanone, CAY- 10401, CAY-10429, CAY-10508, CB-13, CB-25, CB-52, CB-86, CB-86, CBS-0550, CP 47,497, CP 55,244, CP 55,940, CUMYL-5F-PICA, CUMYL-BICA, CUMYL-PICA, CUMYL-PINACA, CUMYL-THPINACA, Dexanabinol. Dimethylheptylpyran, Drinabant, Dronabinol, EAM-2201, EMB-FUBINACA, FAB- 144, FDU-NNE1, FDU-PB-22, FUB- Atorney Docket No. 047162-7542WOl(02749)

[0092] 144, FUB-APINACA, FUB-JWH-018, FUB-PB-22, FUBIMINA, Gemstein, GW-405,833, GW-842.166X, Hemopressin, HU-210, HU-243, HU-308, HU-320, HU-331. HU-336. HU- 345, HU-910, Ibipinabant, IDFP, JNJ 1661010, JNJ 1661010, JTE-907, JTE 7-31, JWH- 007, JWH-015, JWH-018, JWH-019, JWH-030, JWH-051, JWH-073, JWH-081, JWH-098, JWH-116, JWH-122, JWH-133, JWH-139, JWH-147, JWH-149, JWH-161, JWH-164, JWH-167, JWH-175, JWH-176, JWH-182, JWH-184, JWH-185, JWH-192, JWH-193, JWH-194, JWH-195, JWH-196. JWH-197, JWH-198, JWH-199. JWH-200, JWH-203, JWH-210, JWH-229, JWH-249, JWH-250, JWH-251, JWH-302, JWH-307, JWH-359, JWH-369, JWH-370, JWH-398, JWH-424, JZL184, JZL195, Kaempferol, KM-233, L- 759,633, L-759,656, LASSBio-881, LBP-1, Leelamine, Levonantradol, LH-21, LY- 320,135, LY -2183240. NAM-2201, MDM-2201, MDA-7, MDA-19, MDA-77. MDMB- CHMICA, MDMB-CHMINACA, MDMB-FUBINACA, Menabitan, MEPIRAPIM, Methanandamide, MJ-15, MK-9470, MMB-2201, MN-18, MN-25, Nabazenil, Nabilone, Nabitan, Naboctate, NESS-0327, NESS-040C5, NIDA-41020, NM-2201, NMP-7, NNE1, Nonabine 0-224, 0-581, 0-585. 0-606. 0-689, 0-774, 0-806, 0-823, 0-889, 0-1057, O- 1125, 0-1184. 0-1 191, 0-1238. 0-1248, 0-1269. 0-1270. 0-1376, 0-1399. 0-1422, O-

[0093] 1601, 0-1602, 0-1624, 0-1656, 0-1657, 0-1660, 0-1812, 0-1860, 0-1861, 0-1871, O-

[0094] 1918, 0-2048, 0-2050, 0-2093, 0-2113, 0-2220, 0-2365, 0-2372, 0-2373, 0-2383, O-

[0095] 2426, 0-2484, 0-2545, 0-2654, 0-2694, 0-2715. 0-2716, 0-3223, 0-3226,

[0096] Oleoylethanolamide. Olvanil, Org 27569, Org 27759. Org 2831, Org 28611, Org 29647. Otenabant, Palmitoylethanolamide, Parahexyl, PF-03550096, PF-04457845, PF-622, PF- 750, PF-3845, PF-514273, PHOP, PipISB, Pimabine, Pravadoline, Pregnenolone, PSB-SB- 487, PSB-SB-1202, PTI-1, PTI-2, PX-1, PX-2, PX-3, QUCHIC, QUPIC, RCS-4. RCS-8, Rimonabant, Rosonabant, RTI-371, S-444,823, SDB-006, SER-601, SPA-229. SR-144,528, STS-135, Surinabant, Taranabant, Tedalinab, THC-O-acetate, THC-O-phosphate, THJ-018, THJ-2201, Tinabinol, TM-38837, UR-144, URB-447, URB-447, URB-597, URB-602, URB-754, VCHSR, VDM-11, VSN-16, WIN 54,461, WIN 55,212-2, WIN 56,098, XLR- 11, Yangonin, Harmaline, harmala alkaloids, other beta-carbolines, active constituents of ayahuasca. Salvinorin A, Salvinorin B methoxymethyl ether, Salvinorin B ethoxymethyl ether, Piperazines, pFPP, TFMPP, Myristicin, Elemicin, Cryogenine (Vertine), Atropine, Scopolamine, Hyoscyamine, Ibotenic acid, Muscimol, TiHKAL, 2-Me-DET, 4-HO-DBT, 4-HO-DET, 4-HO-DiPT, 4-HO-EPT, 4-HO-McPT, 4-HO-MET, 4-HO-MiPT, 4-HO- MPMI. 4-HO-MPT, 4-HO-aMT, 4-Me-aMT, 4-MeO-MiPT, 4-PrO-DMT, 4.5-MDO-DiPT, 4,5-MDO-DMT, 5 -Ethoxy -aMT, 5-Fluoro-AET, 5-Fluoro-DET, 5-Fluoro-DMT, 5-Fluoro- Atorney Docket No. 047162-7542WOl(02749)

[0097] EPT, 5-Fluoro-MET, 5-MeO-AET, 5-MeO-aMT, 5-MeO-DALT, 5-MeO-DET, 5-MeO- DPT. 5-MeO-EiPT, 5-MeO-MALT, 5-MeO-MiPT, 5-MeO-MPMI. 5-MeO-pyr-T, 5-MeS- DMT, 5-MeO-2-TMT, 5-TFM-DMT, 5-TFMO-DMT, 5,6-MDO-DiPT, 5,6-MDO-DMT, 5,6-MDO-MiPT, 5,6-MeO-MiPT, 5,N,N-TMT, 5F-MPMI, 6-Fluoro-DET, 6-Fluoro-DMT, 6-MeO-THH, 7-Chloro-AMT, 7-F-5-MeO-MET, 4-Acetoxy-DET, 4-Acetoxy-DiPT, 4- Acetoxy-MET. 4- Acetoxy -MiPT, O-Acetylbufotenine, O-Acetylpsilocin, Aeruginascin, Alpha,N-DMT, Alpha,N,O-TMS, Baeocystin, 5-Bromo-DMT, Bufotenin, 5-Chloro-aMT, DALT, Dibutyltryptamine, Diethyltryptamine, Diisopropyltryptamine, 5,N-Dimethyl-N- isopropyltryptamine. Dimethyltryptamine. N.N-Dimethyltryptamine. Dipropyltryptamine. 2,a-Dimethyltryptamine, Ethocybin, Ethylisopropyltryptamine. A-Ethylti ptamine, 5- Fluoro-AMT, 4-Fluoro-5-methoxy-DMT, FT-104, 5-MeO-DMT. 5-Methoxy-N,N- diisopropyltryptamine, 4-Methyl-a-ethyltryptamine, N-Methyl-N-ethyltryptamine, Methyl but l tr ptamine. Methylisopropyltry ptamine. Alpha-Methylserotonin, Alpha- Methyltryptamine, N-Methyltryptamine, MPMI, Norbaeocystin, Propylisopropyltryptamine, 2,N.N-TMT, A.N,N-Trimethyltryptamine, Ketamine, Esketamine, Arketamine, Mitragynine, Y ohimbine, and the like, including a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof

[0098] Suitable AARAs include, for example, clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine. lofexidine, and the like, including solvates, enantiomers, diastereomers, tautomers, and salts (such as pharmaceutically acceptable salts) thereof.

[0099] The therapeutic compositions can be in separate dosage forms or in a single dosage form. A separate dosage form for the therapeutic composition described herein means that the psychedelic agent is present in a first dosage form administrable by any of the delivery methods described herein, and the AARA is present in a second dosage form administrable by any of the delivery7methods described herein. A separate dosage form contains only the psychedelic agent as the active pharmaceutically active ingredient or only the AARA as the active pharmaceutically active ingredient. Each of the separate dosage forms can further independently include one or more pharmaceutically acceptable carriers or excipients, as described herein. Thus, the pharmaceutically acceptable carriers or excipients in the AARA- containing dosage form can be the same or different as the pharmaceutically acceptable carriers or excipients in the psychedelic agent-containing dosage form. Atorney Docket No. 047162-7542WOl(02749)

[0100] The dosage form containing the psychedelic agent, either the single dosage form or the separate dosage form, can be formulated as a dosage form with anti-abuse features. Antiabuse features can include 1) through a prodrug of the psychedelic agent, 2) via an intractable matrix formulation technique, and 3) by antagonist incorporation into the product formulation. In certain embodiments, the anti-abuse properties can include formulation of acid addition salts of the psychedelic agent such that the salt is insoluble in the mucosal membranes of humans, but the psychedelic agent becomes bioavailable when the salt is subjected to the environment in the gastro-intestinal tract. In certain non-limiting embodiments, a dosage form having anti-abuse features can be formulated as described in, for example, US 7,842,307, GB 2238478A, US 7,230,005, WO 2010 / 044842, WO 2013 / 003845, EP 1611880, US 7,510.726, US 7,399,488. US 2009 / 0215808. US 2010 / 0249045, WO 2010 / 105672, WO 2010 / 066034, US 10,420,729, and the like, the disclosures of which are herein incorporated by reference.

[0101] When the dosage form is a single solid dosage form, such as a tablet, the dosage form can be formulated such that the AARA is formulated to be an immediate release component and the psychedelic agent is a delayed or sustained release component. Alternatively, the when the dosage form is a single solid dosage form, such as a tablet, the dosage form can be formulated such that the psychedelic agent is formulated to be an immediate release component and the AARA is a delayed or sustained release component. The AARA and psychedelic dosage forms, either single dosage forms or separate dosage forms, can be formulated as pharmaceutical compositions containing at least pharmaceutically acceptable excipient or carrier as described herein.

[0102] In certain embodiments, the single or separate dosage form contains about 1 to about 1000 mg, or about 1 to about 500 mg, or about 1 to about 400 mg, or about 1 to about 300 mg, or about 1 to about 250 mg, or about 1 to about 200 mg, or about 1 to about 150 mg, or about 1 to about 100 mg, or about 1 to about 90 mg, or about 1 to about 80 mg, or about 1 to about 70 mg, or about 1 to about 60 mg, or about 1 to about 50 mg, or about 1 to about 40 mg, or about 1 to about 30 mg, or about 1 to about 20 mg, or about 1 to about 10 mg of the psychedelic agent, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110,

[0103] 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200,

[0104] 205, 210. 215, 220, 225, 230, 235. 240, 245, 250, 255, 260. 265, 270. 275, 280, 285, 290,

[0105] 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, Atorney Docket No. 047162-7542WOl(02749)

[0106] 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,

[0107] 475, 480. 485, 490, 495, 500, 505. 510, 515, 520, 525, 530, 535, 540. 545, 550, 555, 560,

[0108] 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650,

[0109] 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740,

[0110] 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830,

[0111] 835, 840. 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900. 905, 910, 915, 920,

[0112] 925, 930. 935, 940, 945. 950, 955. 960, 965, 970, 975, 980. 985, 990. 995, or 1000 mg of the psychedelic agent, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0113] In certain embodiments, the single or separate dosage form contains about 5, 10, 15, 20, 25, 30, 35, or 40 mg of the psychedelic agent, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 25 mg of psilocybin, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0114] In certain embodiments, the single or separate dosage form contains about 1 to about 1000 mg, or about 1 to about 500 mg, or about 1 to about 400 mg, or about 1 to about 300 mg, or about 1 to about 250 mg, or about 1 to about 200 mg, or about 1 to about 150 mg, or about 1 to about 100 mg, or about 1 to about 90 mg, or about 1 to about 80 mg, or about 1 to about 70 mg, or about 1 to about 60 mg, or about 1 to about 50 mg, or about 1 to about 40 mg, or about 1 to about 30 mg, or about 1 to about 20 mg, or about 1 to about 10 mg of the AARA, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 0. 1, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110. 115, 120, 125, 130, 135. 140, 145, 150, 155, 160, 165, 170. 175, 180, 185, 190,

[0115] 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280,

[0116] 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370,

[0117] 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460,

[0118] 465, 470. 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530. 535, 540, 545, 550,

[0119] 555, 560. 565, 570, 575. 580, 585. 590, 595, 600, 605, 610. 615, 620. 625, 630, 635. 640,

[0120] 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730,

[0121] 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820,

[0122] 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910,

[0123] 915, 920. 925, 930, 935, 940, 945. 950, 955, 960, 965, 970. 975, 980. 985, 990, 995, or 1000 Atorney Docket No. 047162-7542WOl(02749) mg of the AARA, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0124] In certain embodiments, the single or separate dosage form contains about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, or 10 mg of the AARA, or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof. In certain embodiments, the single or separate dosage form contains about 1 to about 4 mg of guanfacine.

[0125] In some embodiments, the AARA may be guanfacine. In some embodiments, the dose of guanfacine is about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 1 mg / kg. In some embodiments, the dose of guanfacine comprises 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07. 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55. 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1. 1.2, 1.4, 1.6, 1.8. or 2 mg / kg. In some embodiments, the dose of guanfacine comprises about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.4, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of guanfacine comprises at least 0.001, 0.005. 0.01. 0.02, 0.025, 0.03, 0.035, 0.04, 0.045. 0.05. 0.06. 0.07, 0.08, 0.09, 0.1, 0.2. 0.25. 0.3. 0.35. 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.4, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of guanfacine comprises no more than 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45. 0.5, 0.55, 0.6. 0.65. 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2. 1.4, 1.6, 1.8, or 2 mg / kg.

[0126] In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin may be about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg. In some embodiments, the dose of the psilocybin comprises 0.001. 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25, 1.4, 1.5, 1.6, 1.8, or 2 mg / kg. In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin comprises about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05. 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25. 0.3, 0.35. 0.4. 0.45. 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9. 0.95. 1. 1.2, 1.25, 1.4, 1.5, 1.6. 1.8, or 2 mg / kg. In some embodiments, the dose of the psilocybin comprises at least 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25, 1.4, 1.5, 1.6, 1.8, or 2 mg / kg. In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin comprises no more than 0.001, 0.005, 0.01, 0.02, Atorney Docket No. 047162-7542WOl(02749)

[0127] 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1. 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55. 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1. 1.2, 1.25, 1.4, 1.5, 1.6. 1.8, or 2 mg / kg.

[0128] In certain embodiments, the AARA is administered prior to or after administration of the psychedelic agent. In certain embodiments, the AARA can be administered about 1, 5, 10, 15, 30, or 60 minutes before administration of the psychedelic agent. In certain embodiments, the AARA can be administered about 1, 5, 10, 15, 30, or 60 minutes after administration of the psychedelic agent. In certain embodiments, the AARA can be administered about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours before administration of the psychedelic agent. In certain embodiments, the AARA can be administered about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours after administration of the psychedelic agent. In certain embodiments, the AARA and the psychedelic agent are administered concurrently, for example either as part of a single dosage form, or as part of separate dosage forms taken together at the same time.

[0129] In certain embodiments, the psychedelic agent is psilocybin.

[0130] In certain embodiments, the AARA is guanfacine.

[0131] The compositions containing the compound(s) described herein include a pharmaceutical composition comprising at least one compound as described herein and at least one pharmaceutically acceptable carrier. In certain embodiments, the composition is formulated for an administration route such as oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e g, trans- and perivaginally), (intra)nasal and (trans)rectal, intravesical, intrapulmonary. intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0132] Hi. Psilocybin

[0133] Psilocybin is one of the psychedelic agents described herein. Psilocybin, the active compound found in certain psychoactive mushrooms, exists in various polymorphic forms, each with distinct properties that can influence its efficacy and stability.

[0134] Amorphous form

[0135] Among these forms, the amorphous form is notable for its lack of a defined cry stal 1 i ne structure (long-range molecular order). This non-crystalline state ty pically results in enhanced solubility and faster dissolution rates compared to its crystalline counterparts. However, the amorphous form is less stable over time compared to the crystalline Atorney Docket No. 047162-7542WOl(02749) polymorphs, making it more susceptible to degradation, which can impact its therapeutic applications.

[0136] Crystalline forms of psilocybin, including Polymorph A, Polymorph A’, and Polymorph B, exhibit an ordered molecular arrangement that contributes to greater stability compared to amorphous forms. Each has different crystal lattice arrangements, molecular packing, and hydration states (e.g., anhydrous or hydrated forms). These variations can influence key physicochemical properties such as solubility, stability, melting point, and bioavailability. Detailed description of forms of psilocybin can be found in U.S. Patent No. 12,312,375, which is incorporated herein by reference.

[0137] Polymorph A

[0138] Polymorph A is characterized by specific solubility properties, which are crucial for its storage and pharmaceutical formulation. The stability of this polymorph plays a significant role in determining how psilocybin can be effectively used in medical setings, ensuring that the compound maintains its intended effects over time. The crystalline psilocybin in the form Polymorph Ais characterized by one or more of peaks in an X-ray diffraction (XRD) diffractogram: a. peaks at 11.5, 12.0, 14.5, and 17.5, °20±O.l °20; or b. peaks at 11.5, 12.0, 14.5 and 17.5, °20±O. l °20, further characterized by at least one further peak at 19.7, 20.4, 22.2, 24.3 or 25.7 °20±O. l °20.

[0139] The peak at 17.5 °20±O. 1 °20 has a relative intensity compared to the peak at 14.5 °20±O. l °20 of at least 5%, preferably at least 6%, more preferably still at least 7%, through 8%, and 9% to at least 10%.

[0140] In some embodiments, psilocybin Polymorph A exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 1. In some embodiments, the crystalline psilocybin Polymorph A comprises at least 3 peaks of (+0. 1 °20), at least 4 peaks of (+0.1 °20), at least 5 peaks of (±0.1 °20), at least 6 peaks of (±0.1 °20), at least 8 peaks of (±0.1 °20), at least 10 peaks of (±0.1 °20), or at least 15 peaks of (±0.1 °20) of Table 1. A peak at about 17.5. °20±0. 1 °20 distinguishes psilocybin Polymorph A from Polymorph A', in which the peak is absent or substantially absent (i.e. has a relative intensity compared to the peak at 14.5 °20±O. l °20 of less than 2%, more preferably less than 1%).

[0141] Table 1. XRPD peak positions for Polymorph A Atorney Docket No. 047162-7542WOl(02749)

[0142] In some embodiments, crystalline psilocybin Polymorph A is characterized by XRPD diffractogram peaks at 11.5, 12.0, 14.5, and 17.5 °20±O.l °20. In another embodiment, cry stalline psilocybin Polymorph A is further characterized by at least one additional peak, at least two additional peaks, or at least three additional peaks appearing at 19.7, 20.4, 22.2, 24.3 or 25.7 °20±O. 1 °20. In some embodiments, crystalline psilocybin Polymorph A is characterized by XRPD diffractogram peaks at 14.5 and 17.5 °20±O. l °20 with the peak at 17.5 °20 having an intensity which is at least 5%, 6%, 7%, 8%, 9%, or 10% of the intensity of the peak at 14.5 °20. In some embodiments, crystalline psilocybin Polymorph A is absent or substantially absent of an XRPD diffractogram peaks at 10.1. By substantially absent is meant than any XRPD diffractogram peaks at 10. 1 is less than 2% of the intensity of the peak at 14.5 °20, such as less than 1%, or is not detectable in the XRPD diffractogram.

[0143] In some embodiments, cry stalline psilocybin Polymorph A is chemically pure. In some embodiments, cry stalline psilocybin Polymorph A has a chemical purity of greater than 97%. 98%. or 99% by HPLC. In some embodiments, crystalline psilocybin Polymorph A has no single impurity of greater than 1%, more preferably less than 0.5%, including phosphoric acid as measured by31P NMR, and psilocin as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph A has a chemical purity of greater than 97 area %, 98 area %, or 99 area % by HPLC. In some embodiments, crystalline psilocybin Polymorph A has no single impurity greater than 1 area %, more preferably less than 0.5 area % as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph A does not contain psilocin at a level greater than 1 area %, more preferably less than 0.5 area % as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph A does not contain phosphoric acid Atorney Docket No. 047162-7542WOl(02749) at a level greater than 1 weight %, more preferably less than 0.5 weight % as measured by31P NMR. In some embodiments, crystalline psilocybin Polymorph A has a chemical assay of at least 95 weight %, at least 96 weight %, or at least 98 weight %.

[0144] Polymorph A '

[0145] In addition to Polymorph A, there exists a variant known as Polymorph A'. This form shares similarities with Polymorph A but may differ in molecular arrangement or latice parameters. Such differences can lead to unique phy sical and chemical properties that may enhance its application in therapeutic contexts. The crystalline psilocybin Polymorph A' is characterized by or more of peaks in an XRD diffractogram: a. peaks at 11.5, 12.0 and 14.5 °20±O. l °20, but absent or substantially absent of a peak at 17.5 °20±O. l °20; or b. peaks at 11.5, 12.0 and 14.5 °20±O. 1 °20, but absent or substantially absent of a peak at 17.5 °20±O. 1 °20, further characterized by at least one further peak at 19.7, 20.4, 22.2, 24.3 or 25.7 °20±O. l °20.

[0146] By substantially absent of a peak at 17.5 °20±O. 1 °20 is meant, if present, the peak has a relative intensity, compared to a peak at 14.5 °20±O.1 °20, of less than 5%, more preferably less than 4%. through less than 3%, to 2%, 1% or less.

[0147] In some embodiments, psilocybin Polymorph A' exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 2. In some embodiments, the crystalline psilocybin Polymorph A' comprises at least 3 peaks, at least 4 peaks, at least 5 peaks, at least 6 peaks, at least 8 peaks, at least 10 peaks, at least 15 peaks, at least 20 peaks, or at least 25 peaks of (±0. 1 °20) of Table 2 but absent or substantially absent of a peak at 17.5 °20±O. 1 °20.

[0148] Table 2. XRPD peak positions for Polymorph A’ Atorney Docket No. 047162-7542WOl(02749)

[0149] In some embodiments, crystalline psilocybin Polymorph A' is characterized by XRPD diffractogram peaks at 11.5, 12.0, and 14.5 °29±0.1 °20 but substantially absent of a peak at 17.5 °20±O. 1 °20. In another embodiment, cry stalline psilocybin Polymorph A' is further characterized by at least one additional peak appearing at 19.7, 20.4, 22.2, 24.3, or 25.7 °20±O. 1 °20. In another embodiment, crystalline psilocybin Polymorph A' is further characterized by at least two additional peaks appearing at 19.7, 20.4, 22.2, 24.3, or 25.7 °20±O. 1 °20. In another embodiment, crystalline psilocybin Polymorph A' is further characterized, and distinguished from Polymorph A by the presence of a peak appearing at 10.1 °20±O. l °20. In some embodiments, crystalline psilocybin Polymorph A' is characterized by XRPD diffractogram peaks at 14.5 and 17.5 °20±O. l °20 wherein the intensity' of the peak at 17.5 °20 is less than 5%, 4%, 3%, 2%, or 1% of the intensity of the peak at 14.5 °20. In some embodiments, cry stalline psilocybin Polymorph A' is characterized by XRPD diffractogram peaks at 10. 1 and 14.5 °20±O.l °20 wherein the intensity of the peak at 10.1 °20 is at least 1%, 2%. 3%, or 4% of the intensity of the peak at 14.5 °20.

[0150] In another embodiment, crystalline psilocybin Polymorph A' is characterized by having a water content of <0.5% w / w, <0.4% w / w, <0.3% w / w, <0.2% w / w, or <0.1% w / w. In some embodiments, the water content of a compound is measured by Karl Fischer Titration. In some embodiments, crystalline psilocybin Polymorph A' is characterized by having <0.5% w / w loss, <0.4% w / w, <0.3% w / w, <0.2% w / w, <0.1% w / w, in the TGA thermogram between ambient temperature, such as 25° C., and 200° C. In some embodiments, cry stalline psilocybin Polymorph A' loses less than 2% by weight in a loss on Atorney Docket No. 047162-7542WOl(02749) drying test, less than 1% by weight, or less than 0.5% by weight. The loss on drying test is performed at 70° C.

[0151] In some embodiments, crystalline psilocybin Polymorph A' is a highly pure crystalline form of Polymorph A', for example, psilocybin comprises at least 90% by weight, 95%, 99%, 99.5% of Polymorph A'. In some embodiments, crystalline psilocybin Polymorph As is a white to off white solid. In another embodiment, crystalline psilocybin Polymorph A' is chemically pure. In some embodiments, the psilocybin has a chemical purity of greater than 97%, greater than 98%, or greater than 99% by HPLC. In some embodiments, crystalline psilocybin Polymorph A' has no single impurity' of greater than 1% or less than 0.5%, including phosphoric acid as measured by31P NMR, and psilocin as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph A' has a chemical purity of greater than

[0152] 97 area %, greater than 98 area %, or greater than 99 area % by HPLC. In some embodiments, crystalline psilocybin Polymorph A' has no single impurity greater than 1 area % or less than 0.5 area % as measured by HPLC. In some embodiments, cry stalline psilocybin Polymorph A’ does not contain psilocin at a level greater than 1 area % or less than 0.5 area % as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph A' does not contain phosphoric acid at a level greater than 1 weight % or less than 0.5 weight % as measured by31P NMR. In some embodiments, cry stalline psilocybin Polymorph A' has a chemical assay of at least 95 weight %. at least 96 weight %, or at least

[0153] 98 weight %.

[0154] Hydrate A

[0155] In some embodiments, a crystalline form of psilocybin may be a Hydrate A, characterized by one or more of peaks in an XRPD diffractogram: a. peaks at 8.9, 12.6 and 13.8 °20±O. l °20; or b. peaks at 8.9, 12.6 and 13.8 °20±O. 1 °20, further characterized by at least one further peak at 6.5, 12.2, 19.4, 20.4 or 20.8 °20±O. l °20.

[0156] In some embodiments, psilocy bin Hydrate A exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 3. In some embodiments, the crystalline psilocybin Hydrate A comprises at least 3 peaks, at least 4 peaks, at least 5 peaks, at least 8 peaks, or at least 10 peaks of (±0.1 °20) of Table 3.

[0157] Table 3. XRPD peak positions for Hydrate A Attorney Docket No. 047162-7542WOl(02749)

[0158] In some embodiments, crystalline psilocybin Hydrate A is characterized by XRPD diffractogram peaks at 8.9, 12.6 and 13.8 °29±0.1 °20. In another embodiment, crystalline psilocybin Hydrate A is further characterized by at least one peak or at least two peaks appearing at 6.5, 12.2, 19.4, 20.4 or 20.8 °20±0.1 °20.

[0159] In another embodiment, crystalline psilocybin Hydrate A is characterized by having a water content of between 10 and 18%, such as between 12 and 16%. In some embodiments, crystalline psilocybin Hydrate A is characterized by having a weight loss in the TGA thermogram of betw een 10 and 18% betw een ambient temperature, including about 25° C., and 120° C. In some embodiments, crystalline psilocybin Hydrate A is a highly pure crystalline form of Hydrate A. for example, psilocybin comprises at least 90% by weight, such as 95%, such as 99%, such as 99.5% of Hydrate A.

[0160] Polymorph B

[0161] Furthermore, Polymorph B represents another crystalline form of psilocybin, distinguished by its own solubility and stability7characteristics. The heating of Polymorph A Attorney Docket No. 047162-7542WOl(02749) or A' results in an endothermic event having an onset temperature of circa 150° C. corresponding to solid-solid transition of Polymorph A or Polymorph A' to Polymorph B. In some embodiments, a crystalline form of psilocybin. Polymorph B, is characterized by one or more of peaks in an XRPD diffractogram: a. peaks at 11.1, 11.8 and 14.3 °20±0.1 °20; or b. peaks at 11. 1, 11.8 and 14.3 °20±O. 1 °20, further characterized by at least one further peak at 14.9, 15.4, 19.3, 20.0 or 20.6 °20±O. l °20;

[0162] In some embodiments, psilocybin Polymorph B exhibits an XRPD diffractogram characterized by the diffractogram summarized in Table 4. In some embodiments, the crystalline psilocybin Polymorph B comprises at least 3 peaks, at least 4 peaks, at least 8 peaks, or at least 10 peaks of (±0.1 °20) of Table 4.

[0163] Table 4. XRPD peak positions for Polymorph B

[0164] In some embodiments, crystalline psilocybin Polymorph B is characterized by XRPD diffractogram peaks at 11.1, 11.8 and 14.3 °20±O. l °20. In some embodiments, crystalline Atorney Docket No. 047162-7542WOl(02749) psilocybin Polymorph B is further characterized by at least one peak or at least two peaks appearing at 14.9, 15.4, 19.3, 20.0 or 20.6 °20±0.1 °20.

[0165] In some embodiments, crystalline psilocybin Polymorph B is characterized by having a water content of <0.5% w / w, <0.4% w / w, <0.3% w / w, <0.2% w / w, or <0.1% w / w, in the TGA thermogram between ambient temperature, including about 25° C., and 200° C. In some embodiments, crystalline psilocybin Polymorph B loses less than 2% by weight in a loss on drying test, less than 1% by weight, or less than 0.5% by weight. The loss on drying test is performed at 70° C.

[0166] In some embodiments, crystalline psilocybin Polymorph B is a highly pure crystalline form of Polymorph B, for example, psilocybin comprises at least 90% by weight, 95%, 99%, or 99.5% of Polymorph B. In some embodiments, crystalline psilocybin Polymorph B is chemically pure. In some embodiments, the psilocybin has a chemical purity of greater than 97%, greater than 98%, or greater than 99% by HPLC. In some embodiments, crystalline psilocybin Polymorph B has no single impurity of greater than 1% or less than 0.5%, including phosphoric acid as measured by31P NMR, and psilocin as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph B has a chemical purity of greater than 97 area %, greater than 98 area %, or greater than 99 area % by HPLC. In some embodiments, crystalline psilocybin Polymorph B has no single impurity' greater than 1 area % or less than 0.5 area % as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph B does not contain psilocin at a level greater than 1 area % or less than 0.5 area % as measured by HPLC. In some embodiments, crystalline psilocybin Polymorph B does not contain phosphoric acid at a level greater than 1 weight % or less than 0.5 weight % as measured by?1P NMR. In some embodiments, crystalline psilocybin Polymorph B has a chemical assay of at least 95 weight %, at least 96 weight %, or at least 98 weight %.

[0167] Non-Limiting Discussion

[0168] MDMA is currently in Phase 3 clinical trials to treat post-traumatic stress disorder (PTSD) and appears to show substantial efficacy in the reduction of PTSD symptoms. In certain embodiments, MDMA can augment psychotherapy for PTSD by increasing atention to traumatic memories or by strengthening extinction learning. PTSD is characterized by changes in learning and, in this context, enhancement of extinction learning may improve PTSD treatments. In mice, fear extinction enhancement studies show MDMA to enhance extinction of auditory fear associations through serotonin (5-HT) release, and this effect can Atorney Docket No. 047162-7542WOl(02749) be recapitulated via direct infusion of MDMA into either medial prefrontal cortex (mPFC) or amygdala.

[0169] MDMA enables patients to revisit traumatic memories with greater ease, leading it to be called an “entactogen” (“going within to bring out”). Drug discrimination studies show that animals distinguish between entactogens and classic psychedelics (5-HT2A agonists), and human subjective effects of entactogens are also distinct from classic psychedelics. Mechanistically, entactogens act like stimulants to release norepinephrine (NE) and dopamine (DA) through monoamine transporters, but differ from stimulants in that they also release 5-HT. Within the entactogen class, there is substantial diversity of in vitro selectivity for monoamine transporters. The link between in vivo monoamine-releasing effects of MDMA and specific mechanistic effects relevant to therapeutic plasticity remains unclear.

[0170] Pharmacological dissociation studies have established individual monoamines’ role in MDMA’s behavioral effects. 5-HT release leads to pro-social behavior through 5-HTIB activation in nucleus accumbens and fear extinction enhancement through the 5-HT2A receptor. The rewarding and addictive effects of MDMA are mediated by dopamine release in nucleus accumbens. Locomotor increase by MDMA involves the noradrenergic ai receptor in rodents and in humans, NE release contributes to euphoria and cardiovascular activation. Further delineating receptor-dependent effects of MDMA may allow the development of entactogens with improved efficacy in PTSD and tolerability.

[0171] Different entactogens were investigated for induction of fear extinction behavior. 5- HT and NE release, and 5-HT2A dependent behavior. Fear extinction was systematically compared across entactogens to determine if other drugs in this class share putative therapeutic effects with MDMA. To characterize neuromodulator effects, in vivo neurotransmiter release measurements and behavior was compared across entactogens and psychedelic drugs. Pharmacological manipulations revealed a previously unreported role for NE in interacting with 5-HT2A agonism in the behavioral effects of MDMA.

[0172] Since MDMA is hypothesized to act as a treatment for PTSD by fear extinction enhancement, fear extinction enhancement to auditory cues was assessed using a three-day paradigm to compare entactogens. To determine the distinct roles of 5-HT and NE release in entactogen effects, in vivo behavioral and physiological approaches were used to detangle distinct neuromodulatory release properties between entactogens. In vivo 5-HT2A receptor activity can be identified using the head twitch response (HTR), a sudden rapid movement of the head which occurs with hallucinogenic 5-HT2A agonists and indirectly by drugs that induce serotonin release. An automated magnetometer HTR assay was used to assess 5-HT2A Atorney Docket No. 047162-7542WOl(02749) activity of entactogen drugs. Furthermore, fiber photometry' and fluorescent GPCR-based sensors for 5-HT and NE were used to separately identify dynamics of neuromodulator release after drug injections. This approach enables high temporal resolution and high specificity measurement of neurotransmiter release, allowing for precise observation of neuromodulator levels after injection of entactogens.

[0173] NE releasing effects of entactogens and HTR

[0174] NE release dynamics were determined, since in vitro transporter affinity studies predict differences in NE release properties across entactogens. Using fiber photometry of GPCR based sensors, in vivo NE dynamics in the mPFC (FIG. 1A) were measured with high temporal resolution after administration of entactogens. The physical manipulation involved in intraperitoneal injections evokes a transient increase in NE (FIGs. IB).

[0175] Without being bound by theory, it was hypothesized that NE can suppress the head twitch response of entactogens (FIG. 1C-D). Since entactogens induce NE release via presynaptic NE transporters (NET), reboxetine (a NET inhibitor) was used (1 minute pretreatment; reboxetine+MDMA) to block NE release from MDMA. It was confirmed that co-administration of reboxetine one minute before MDMA injection suppresses NE release using fiber photometry' of the NE GRAB sensor (GRAB-NE2h, FIG. IE). This effect was selective: NET inhibition (reboxetine, 10 mg / kg, n=7) but not SERT inhibition (fluoxetine, 10 mg / kg, n=7) suppressed NE release (FIG. IE).

[0176] Saline+MDMA and reboxetine+MDMA were compared to determine whether NE release is responsible for the low HTR behavior of MDMA. In agreement with this hypothesis, reboxetine+MDMA elicited a greater number of head twitches than saline+MDMA (30 minutes; FIG. IF). Temporally, the head twitch increases in the reboxetine+MDMA group were sustained for at least 30 minutes (FIG. IF right). Without being bound by theory, it is believed that lower NE leads to higher head twitches for MDMA.

[0177] NE blockade of HTR mediated through the «2 adrenergic receptor

[0178] An a2 antagonist yohimbine (2 mg / kg, n=5) was administered before MDMA (yohimbine+MDMA; FIGs. 2A-2C). Indeed, yohimbine+MDMA increased the HTR relative to vehicle+MDMA (FIGs. 3A-3C, Unpaired T test p=0.0133, t=3.166, df=8). Like reboxetine, suppression of the noradrenergic blocking effect was most pronounced after the initial administration and sustained for 30 minutes (FIGx. 4A-4C). Atorney Docket No. 047162-7542WOl(02749)

[0179] Since blocking the ai receptor unmasked MDMA's 5-HT2A effect on head twitches, activation of this receptor with guanfacine (FIGs. 3A-3C) was undertaken. Previously, it was found that blocking NE release from MDMA with reboxetine led to more head twitches. If the suppressive effect of NE is mediated by the 012 receptor, then adding guanfacine (MDMA+reboxetine+guanfacine) should reduce head twitches. In this new cohort (MDMA+reboxetine+ / -guanfacine, 0. 15 mg / kg), 012 agonism suppressed head twitches (FIG. 3B).

[0180] To beter understand the implications of U2- -HT2A receptor interactions in behavior, guanfacine was tested against psilocybin, a 5-HT2A receptor agonist with more robust HTR (FIGx. 4A-4C). Indeed, guanfacine could suppress the HTR of psilocybin (psilocybin+guanfacine vs. psilocybin+saline (n=7; FIG. 4B) and prevented the previously identified temporal peak. The noradrenergic 012 NE receptor bidirectionally modulates the 5- HT2A effects of MDMA and can also suppress those effects for a classic psychedelic.

[0181] It was found that MDMA’s supraphysiological NE release opposes the head twitch behavior (a downstream effect of 5-HT2A agonism) through 0.2 noradrenergic receptor activation. Thus, this study uncovered a role for NE in opposing indirect 5-HT2A effects.

[0182] Despite observing that NE suppresses the head twitch response, the specific neural circuits subserving this opponency have not been identified. Local infusion of 5-HT2A agonists into the mPFC can induce the HTR, however the specificity and circuit basis of this phenomenon remain unknown. Head twitches also coincide with apparent widespread activation of cortical and hippocampal circuits. NE release by MDMA acts on the 012 receptor to oppose 5-HT2A agonist effects - intriguingly, the ai receptor has well characterized effects on layer V pyramidal cells in the mPFC, which also have been suggested as mediating 5- HT2A effects. Noradrenergic effects of MDMA have also been identified as contributing to subjective euphoria from MDMA in humans and increased locomotion in mice. Circuitspecific recordings and manipulations of the NE pathway may further delineate how the distinct monoaminergic effects of MDMA interact with one another.

[0183] Using fluorescent GRAB sensors and fiber photometry provided important insight into the in vivo mechanisms of entactogens. The combination of high temporal resolution and molecular specificity permited us to make inferences about neuromodulatory release properties of entactogens. This approach was utilized to observe the precise manipulation of NE release by MDMA and NET blockade. These sensors permit spatial and cell-type localization in combination with genetically modified animals, which can be used to further Atorney Docket No. 047162-7542WOl(02749) demarcate specific regional differences in entactogen induced monoamine release and identify the downstream circuits affected by drug administration.

[0184] 5-HT2A agonism plays a key role in generating structural plasticity after psychedelics and may also contribute to fear extinction enhancement. An important caveat is that MDMA also induces social behaviors in mice and humans - enhancing prosocial behavior and trust could also influence psychotherapy efficacy. Since MDMA-assisted psychotherapy may become a critically needed treatment for PTSD, understanding the mechanism of this therapeutic effect is imperative. The results herein point to distinct, surprising, and unexpected neuromodulatory roles of NE and 5-HT in MDMA's effects.

[0185] The compounds described herein can possess one or more stereocenters, and each stereocenter can exist independently in either the (R) or (S) configuration. In certain embodiments, compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds described herein encompass racemic, optically- active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In certain embodiments, a mixture of one or more isomer is utilized as the therapeutic compound described herein. In other embodiments, compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis and / or separation of a mixture of enantiomers and / or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.

[0186] The methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), solvates, amorphous phases, and / or pharmaceutically acceptable salts of compounds having the structure of any compound(s) described herein, as well as metabolites and active metabolites of these compounds having the same type of activity. Solvates include water, ether (e.g., tetrahydrofuran, methyl tert-butyl ether) or alcohol (e.g., ethanol) solvates, acetates and the like. In certain embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, and ethanol. In other embodiments, the compounds described herein exist in unsolvated form. Atorney Docket No. 047162-7542WOl(02749)

[0187] In certain embodiments, the compound(s) described herein can exist as tautomers. All tautomers are included within the scope of the compounds presented herein.

[0188] In certain embodiments, compounds described herein are prepared as prodrugs. A “prodrug” refers to an agent that is converted into the parent drug in vivo. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In other embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.

[0189] In certain embodiments, sites on, for example, the aromatic ring portion of compound(s) described herein are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the aromatic ring structures may reduce, minimize or eliminate this metabolic pathway. In certain embodiments, the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a deuterium, a halogen, or an alkyl group.

[0190] Methods of Treating, Ameliorating, and / or Preventing

[0191] The disclosure includes a method of treating, ameliorating, and / or preventing post- traumatic stress disorder (PTSD) using the compounds and / or compositions described herein. The methods described herein also serve to treat, ameliorate, and / or prevent at least one symptom of PTSD. Symptoms of PTSD include, but are not limited to, feeling upset by things that remind a person of what happened, having nightmares, vivid memories, or flashbacks of the event that make a person feel like the traumatic event is happening all over again, feeling emotionally cut off from others, feeling numb or losing interest in things you used to care about, feeling constantly on guard, feeling irritated or having angry outbursts, having difficulty sleeping, having trouble concentrating, being jumpy or easily startled, frequently avoiding places or things that remind a person of what happened, using alcohol and / or drugs to numb feelings, consider harming yourself or others, working all the time to occupy the mind, pulling away from other people and become isolated, and the like. In certain embodiments, the methods described herein also serve to treat, ameliorate, and / or prevent at least two, three, four, five, or more symptoms of PTSD. The methods described herein can be used in administering any of the doses of the entactogen, NEI, psychedelic agent, or AARA described herein.

[0192] In certain embodiments, a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof is provided. In certain embodiments, the Atorney Docket No. 047162-7542WOl(02749) method includes administering to the subject a therapeutically effective amount of at least one norepinephrine inhibitor (NEI), or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof. In certain embodiments, the method includes administering to the subject a therapeutically effective amount of at least one entactogen, or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof. In certain embodiments, the post- traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0193] In certain embodiments, a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof is provided. In certain embodiments, the method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a norepinephrine inhibitor (NEI), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the method includes administering to the subj ect a pharmaceutical composition comprising a therapeutically effective amount of an entactogen, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are formulated as a single dosage form or as separate dosage forms. In certain embodiments, the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0194] In certain embodiments, the NEI, or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof, is selected from the group consisting of atomoxetine (( / ?)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan- 1 -amine), reboxetine (rel-(2J?)-2- [(R)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine), viloxazine ((RS)-2-[(2- ethoxyphenoxy)methyl]morpholine), amedalin (UK-3540-1), Daledalin (UK-3557-15), edivoxetine (LY-2216684), esreboxetine (AXS-14; PNU-165442G), lortalamine (LM-1404), nisoxetine (LY-94,939), talopram (tasulopram) (Lu 3-010), talsupram (Lu 5-005), and tandamine (AY-23,946).

[0195] In certain embodiments, the entactogen, or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof, is selected from the group consisting of MDMA (3,4-methylenedioxymethamphetamine), MDA (3,4- methylenedi oxyamphetamine), MDEA (3,4-methylenedioxy-N-ethylamphetamine), MDOH (3, 4-methylenedioxy-N-hydroxy amphetamine), MBDB (1 ,3-benzodioxolyl-N- methylbutanamine), 5-APB (l-benzofuran-5-ylpropan-2-amine), 5-MAPB (l-(benzofuran-5- yl)-N-methylpropan-2-amine), 6- APB (6-(2-aminopropyl)benzofuran), 6-MAPB (1- Atorney Docket No. 047162-7542WOl(02749)

[0196] (benzofuran-6-yl)-N-methylpropan-2-amine), methylone (3,4-methylenedioxy-N- methylcathinone), mephedrone (4-methylmethcathinone). GHB (v-hydroxybutyric acid). aMT (a-methyltryptamine), a.ET (a-ethyltryptamine), and MDAI (5,6-methylenedioxy-2- aminoindane).

[0197] In certain embodiments, the NEI is reboxetine. In certain embodiments, the entactogen is MDMA. In certain embodiments, the subject is administered about 1 mg to about 1000 mg of the NEI.

[0198] In certain embodiments, the subject is administered about 1 to about 1000 mg of the entactogen.

[0199] In certain embodiments, the NEI is administered to the subject 1 minute to 24 hours before the entactogen is administered to the subject.

[0200] In certain embodiments, the NEI and the entactogen are administered concurrently.

[0201] In certain embodiments, the NEI and the entactogen are in a single dosage form.

[0202] In certain embodiments, the single dosage form includes an anti-abuse formulation.

[0203] In certain embodiments, the NEI and the entactogen are independently administered by a route independently selected from the group consisting of oral transdermal, transmucosal, (intrajnasal and (trans)rectal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0204] In certain embodiments, a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof is provided. In certain embodiments, the method includes administering to the subject a therapeutically effective amount of at least one a2A-adrenergic receptor agonist (AARA), or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof. In certain embodiments, the method includes administering to the subject a therapeutically effective amount of at least one psychedelic agent, or a solvate, enantiomer, diastereomer, tautomer, or (pharmaceutically acceptable) salt thereof. In certain embodiments, the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0205] In certain embodiments, a method of treating, ameliorating, or preventing post- traumatic stress disorder in a subject in need thereof is provided. In certain embodiments, the method includes administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a c -adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the method includes administering to the subject a pharmaceutical Atorney Docket No. 047162-7542WOl(02749) composition comprising a therapeutically effective amount of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In certain embodiments, the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms. In some embodiments, the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent may be formulated as a single dosage form. In other embodiments, the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent may be formulated as separate dosage forms. In certain embodiments, the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0206] In certain embodiments, the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methy lnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, tautomer thereof.

[0207] In certain embodiments, the psychedelic agent comprises psilocybin, 2C-B (4-bromo- 2,5-dimethoxyphenethylamine), ketamine, tryptamine, a tryptamine derivative, DMT (N,N- dimethyltryptamine), 5-MeO-DMT (5-methoxy-dimethyltryptamine). 5-MeO-MiPT (5- methoxy-N-methyl-N-isopropyltryptamine), LSA (d-lysergic acid amide), and LSD (lysergic acid diethylamide), or a solvate, enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.

[0208] In certain embodiments, the AARA is guanfacine.

[0209] In certain embodiments, the psychedelic agent is psilocybin.

[0210] In certain embodiments, the subject is administered about 1 to about 1000 mg of the AARA. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.005 mg / kg to about 0.10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of the AARA. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20. 21, 22, 23, 24, or 25 mg / kg. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or Atorney Docket No. 047162-7542WOl(02749) tautomer thereof comprises a dose of about 0.001. 0.005, 0.01, 0.02, 0.03, 0.04, 0.05. 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25. 0.3, 0.4, 0.5, 0.6. 0.7, 0.8, 0.9, 1, 2, 3, 4. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mg / kg. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of at least 0.001, 0.005, 0.01, 0.02, 0.03, 0.04. 0.05. 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4. 0.5, 0.6, 0.7, 0.8. 0.9, 1, 2. 3. 4, 5, 6. 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mg / kg. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of no more than 0.001, 0.005. 0.01. 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4. 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mg / kg.

[0211] In some embodiments, the AARA may be guanfacine. In some embodiments, the dose of guanfacine may be about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 1 mg / kg. In some embodiments, the dose of guanfacine comprises 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.4, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of guanfacine comprises about 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045. 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2. 0.25. 0.3, 0.35. 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1 , 1.2, 1.4, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of guanfacine comprises at least 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65. 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2. 1.4, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of guanfacine comprises no more than 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.4, 1.6, 1.8, or 2 mg / kg.

[0212] In certain embodiments, the subject is administered about 1 to about 1000 mg of the psychedelic agent. In some embodiments, the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of the psychedelic agent. In some embodiments, the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.00005, 0.0001, 0.0005, Atorney Docket No. 047162-7542WOl(02749)

[0213] 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9. 1, 1.1, 1.5, 2, 2.5, 3, 3.5, 4,

[0214] 4.5, 5, 5.5, 6. 6.5, 7, 7.5, or 8 mg / kg. In some embodiments, the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,

[0215] 5.5, 6, 6.5, 7. 7.5, or 8 mg / kg. In some embodiments, the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of at least 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,

[0216] 5.5, 6, 6.5, 7, 7.5, or 8 mg / kg. In some embodiments, the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of no more than 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.5, 2, 2.5, 3, 3.5, 4,

[0217] 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8 mg / kg.

[0218] In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin may be about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg. In some embodiments, the dose of the psilocybin comprises 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1. 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75. 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25. 1.4, 1.5, 1.6. 1.8, or 2 mg / kg. In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin comprises about 0.001 , 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25, 1.4, 1.5, 1.6, 1.8, or 2 mg / kg. In some embodiments, the dose of the psilocybin comprises at least 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25, 1.4, 1.5,

[0219] 1.6, 1.8, or 2 mg / kg. In some embodiments, the psychedelic agent may be psilocybin. In some embodiments, the dose of the psilocybin comprises no more than 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.035. 0.04. 0.045, 0.05, 0.06, 0.07. 0.08. 0.09. 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.2, 1.25, 1.4, 1.5, 1.6, 1.8, or 2 mg / kg.

[0220] In certain embodiments, the AARA is guanfacine and the psychedelic agent is psilocybin.

[0221] In certain embodiments, the AARA and the psychedelic agent are administered concurrently. Atorney Docket No. 047162-7542WOl(02749)

[0222] In certain embodiments, the AARA and the psychedelic agent are in a single dosage form.

[0223] In certain embodiments, the single dosage form includes an anti-abuse formulation.

[0224] In certain embodiments, the AARA and the psychedelic agent are independently administered by various routes. In some embodiments, the administration route for the AARA and the psychedelic agent may be independently selected. In some embodiments, the administration routes for the AARA and the psychedelic agent include but are not limited to buccal, rectal, pleural, peritoneal, vaginal, epidural, intratracheal, intraocular, intraperitoneal, oral transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonary. intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalational, and topical administration.

[0225] In some embodiments, the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent each independently further comprise at least one pharmaceutically acceptable carrier or excipient.

[0226] In some embodiments, the method described herein comprises: administering to the human subject: a pharmaceutical composition comprising a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and a pharmaceutical composition comprising a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA is administered (i) more than about 24 hours before administration of the pharmaceutical composition comprising the psychedelic agent or (ii) about 20 minutes or about 45 minutes before administration of the pharmaceutical composition comprising the psychedelic agent.

[0227] The methods described herein include administering to the subject a therapeutically effective amount of at least one compound described herein, which is optionally formulated in a pharmaceutical composition. In various embodiments, a therapeutically effective amount of at least one compound described herein present in a pharmaceutical composition is the only therapeutically active compound in a pharmaceutical composition. In certain embodiments, the method further comprises administering to the subject an additional therapeutic agent that treats PTSD or symptoms thereof.

[0228] In certain embodiments, administering the compound(s) described herein to the subject allows for administering a lower dose of the additional therapeutic agent as compared to the dose of the additional therapeutic agent alone that is required to achieve similar results in treating PTSD or symptoms thereof in the subject. For example, in certain embodiments, Atorney Docket No. 047162-7542WOl(02749) the compound(s) described herein enhance(s) the activity of the additional therapeutic compound, thereby allowing for a lower dose of the additional therapeutic compound to provide the same effect.

[0229] In certain embodiments, the compound(s) described herein and the therapeutic agent are co-administered to the subject. In other embodiments, the compound(s) described herein and the therapeutic agent are co-formulated and co-administered to the subject.

[0230] In certain embodiments, the subject is a mammal. In other embodiments, the mammal is a human.

[0231] In some embodiments, the pharmaceutical composition comprising the AARA may be administered to the subject by various routes. The route of administration includes, but is not limited to buccal, rectal, pleural, peritoneal, vaginal, epidural, intratracheal, intraocular, intraperitoneal, oral, transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonaiy . intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalational, and topical administration.

[0232] In some embodiments, the pharmaceutical composition comprising the psychedelic agent is administered to the subject by various routes. The route of administration includes, but is not limited to transdermal, transmucosal, (intrajnasal and (trans)rectal, intravesical, intrapulmonaiy , intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalational. or topical administration.

[0233] In some embodiments, the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In some embodiments, the AARA comprises guanfacine.

[0234] In some embodiments, the psychedelic agent comprises psilocybin, 2C-B (4-bromo- 2,5-dimethoxyphenethylamine), ketamine, tryptamine, a tryptamine derivative, DMT (N,N- dimethyltryptamine), 5-MeO-DMT (5 -methoxy -dimethyl tryptamine). 5-MeO-MiPT (5- methoxy-N-methyl-N-isopropyltryptamine), LSA (d-lysergic acid amide), LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof. In some embodiments, the psychedelic agent comprises psilocybin. In other embodiments, the psychedelic agent comprises 5-MeO-DMT. In some embodiments, the AARA comprises guanfacine, wherein the psychedelic agent comprises psilocybin, and Atorney Docket No. 047162-7542WOl(02749) wherein the guanfacine and the psilocybin are the only therapeutically effective agents administered to the human subject.

[0235] Combination Therapies

[0236] The compounds useful within the methods described herein can be used in combination with one or more additional therapeutic agents useful for treating PTSD or symptoms thereof. These additional therapeutic agents may comprise compounds that are commercially available or synthetically accessible to those skilled in the art. These additional therapeutic agents are known to treat or reduce the symptoms, of PTSD or symptoms thereof.

[0237] In various embodiments, a synergistic effect is observed when a compound as described herein is administered with one or more additional therapeutic agents or compounds. A synergistic effect may be calculated, for example, using suitable methods such as, for example, the Sigmoid-Emax equation (Holford & Scheiner, 1981, Clin. Pharmacokinet. 6:429-453), the equation of Loewe additivity (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol. 114:313-326) and the median-effect equation (Chou & Talalay, 1984, Adv. Enzyme Regul. 22:27-55). Each equation referred to above may be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and combination index curve, respectively.

[0238] Administration / Dosage / Formulations

[0239] The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the subject either prior to or after the onset of PTSD or symptoms thereof. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

[0240] Administration of the compositions described herein to a patient, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to treat PTSD or symptoms thereof in the patient. An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the state of the disease or disorder in the patient; the age, Atorney Docket No. 047162-7542WOl(02749) sex, and weight of the patient; and the ability of the therapeutic compound to treat a PTSD or symptoms thereof in the patient. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for a therapeutic compound described herein is from about 1 and 5,000 mg / kg of body weight / per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.

[0241] Actual dosage levels of the active ingredients in the pharmaceutical compositions described herein may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0242] In particular, the selected dosage level depends upon a variety’ of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.

[0243] A medical doctor, e.g, physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds described herein employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0244] In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary' dosages for the patients to be treated: each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the compound(s) described herein are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such a therapeutic compound. Atorney Docket No. 047162-7542WOl(02749)

[0245] In certain embodiments, the compositions described herein are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions described herein comprise a therapeutically effective amount of a compound described herein and a pharmaceutically acceptable carrier.

[0246] The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, sodium chloride, or poly alcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

[0247] In certain embodiments, the compositions described herein are administered to the patient in dosages that range from one to five times per day or more. In other embodiments, the compositions described herein are administered to the patient in range of dosages that include, but are not limited to, once every day, every two days, every three days to once a week, and once every two weeks. It is readily apparent to one skilled in the art that the frequency of administration of the various combination compositions described herein varies from individual to individual depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, administration of the compounds and compositions described herein should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient is determined by the atending physician taking all other factors about the patient into account.

[0248] The compound(s) described herein for administration may be in the range of from about I pg to about 10,000 mg, about 20 pg to about 9,500 mg, about 40 pg to about 9,000 mg, about 75 pg to about 8,500 mg, about 150 pg to about 7,500 mg, about 200 pg to about 7,000 mg, about 350 pg to about 6,000 mg, about 500 pg to about 5,000 mg, about 750 pg to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg. about 25 mg to about 1,500 mg, about 30 mg to about 1,000 mg, about 40 mg to about 900 mg, about 50 mg to about 800 mg, about 60 mg to about 750 mg, about 70 Atorney Docket No. 047162-7542WOl(02749) mg to about 600 mg, about 80 mg to about 500 mg, and any and all whole or partial increments therebetween.

[0249] In some embodiments, the dose of a compound described herein is from about 1 mg and about 2,500 mg. In some embodiments, a dose of a compound described herein used in compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5.000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg. or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.

[0250] In certain embodiments, a composition as described herein is a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound described herein, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or disorder in a patient.

[0251] Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, know n to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g, lubricants, preservatives, stabilizers, weting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and / or aromatic substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic agents.

[0252] Routes of administration of any of the compositions described herein include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the compositions described herein can be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (c.g.. sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g, trans- and perivaginally). (intra)nasal and (trans)rectal), intravesical, intrapulmonary. intraduodenal, intragastrical, intrathecal, Atorney Docket No. 047162-7542WOl(02749) subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0253] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry’ powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions described herein are not limited to the particular formulations and compositions that are described herein.

[0254] Oral Administration

[0255] For oral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules, caplets and gelcaps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.

[0256] For oral administration, the compound(s) described herein can be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g, polyvinylpyrrolidone, hydroxypropylcellulose or hydroxypropyl methylcellulose); fdlers (e.g, cornstarch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g, magnesium stearate, talc, or silica); disintegrates (e.g, sodium starch gly collate); or weting agents (e.g, sodium lauryl sulphate). If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY™ White, 32K18400). Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g, sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g, Atorney Docket No. 047162-7542WOl(02749) lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g.. methyl or propyl p-hydroxy benzoates or sorbic acid).

[0257] Compositions as described herein can be prepared, packaged, or sold in a formulation suitable for oral or buccal administration. A tablet that includes a compound as described herein can, for example, be made by compressing or molding the active ingredient, optionally with one or more additional ingredients. Compressed tablets may be prepared by compressing, in a suitable device, the active ingredient in a free-flowing form such as a powder or granular preparation, optionally mixed w ith one or more of a binder, a lubricant, an excipient, a surface active agent, and a dispersing agent. Molded tablets may be made by molding, in a suitable device, a mixture of the active ingredient, a pharmaceutically acceptable carrier, and at least sufficient liquid to moisten the mixture. Pharmaceutically acceptable excipients used in the manufacture of tablets include, but are not limited to, inert diluents, granulating and disintegrating agents, dispersing agents, surface-active agents, disintegrating agents, binding agents, and lubricating agents.

[0258] Suitable dispersing agents include, but are not limited to, potato starch, sodium starch gly collate, poloxamer 407, or poloxamer 188. One or more dispersing agents can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more dispersing agents can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%. 0.05%. 0.1%, 0.5%, 1%. 2%, 3%. 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0259] Surface-active agents (surfactants) include cationic, anionic, or non-ionic surfactants, or combinations thereof. Suitable surfactants include, but are not limited to, behentrimonium chloride, benzalkonium chloride, benzethonium chloride, benzododecinium bromide, carbethopendecinium bromide, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cetylpy ridine chloride, didecyldimethy lammonium chloride, dimethyldioctadecylammonium bromide, dimethyldioctadecylammonium chloride, domiphen bromide, lauryl methyl gluceth-10 hydroxypropyl dimonium chloride, tetramethylammonium hydroxide, thonzonium bromide, stearalkonium chloride, octenidine dihydrochloride, olaflur, N-oleyl-l,3-propanediamine, 2-aciylamido-2-methylpropane sulfonic acid, alky I benzene sulfonates, ammonium lauryl sulfate, ammonium perfluorononanoate, docusate, disodium cocoamphodiacetate. magnesium laureth sulfate, perfluorobutanesulfonic acid, perfluorononanoic acid, perfluorooctanesulfonic acid, perfluorooctanoic acid, potassium Atorney Docket No. 047162-7542WOl(02749) lauryl sulfate, sodium alkyl sulfate, sodium dodecyl sulfate, sodium laurate, sodium laureth sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium nonanoyloxybenzenesulfonate, sodium pareth sulfate, sodium stearate, sodium sulfosuccinate esters, cetomacrogol 1000, cetostearyl alcohol, cetyl alcohol, cocamide diethanolamine, cocamide monoethanolamine, decyl glucoside, decyl polyglucose, glycerol monostearate, octylphenoxy poly ethoxy ethanol CA-630, isoceteth-20, lauryl glucoside, octylphenoxypoly ethoxyethanol P-40, Nonoxynol-9, Nonoxynols, nonyl phenoxypolyethoxylethanol (NP-40), octaethylene glycol monododecyl ether, N-octyl beta- D-thioglucopyranoside, octy l glucoside, oleyl alcohol, PEG- 10 sunflower glycerides, pentaethylene glycol monododecyl ether, polidocanol, poloxamer, poloxamer 407, polyethoxylated tallow amine, polyglycerol polyricinoleate, polysorbate, polysorbate 20. polysorbate 80, sorbitan, sorbitan monolaurate, sorbitan monostearate, sorbitan tristearate, stearyl alcohol, surfactin, Triton X-100, and Tween 80. One or more surfactants can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more surfactants can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0260] Suitable diluents include, but are not limited to, calcium carbonate, magnesium carbonate, magnesium oxide, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate, Cellactose ® 80 (75 % a- lactose monohydrate and 25 % cellulose powder), mannitol, pre-gelatinized starch, starch, sucrose, sodium chloride, talc, anhydrous lactose, and granulated lactose. One or more diluents can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more diluents can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%. 0.05%. 0.1%, 0.5%, 1%. 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0261] Suitable granulating and disintegrating agents include, but are not limited to, sucrose, copovidone, com starch, microcry stalline cellulose, methyl cellulose, sodium starch gly collate, pregelatinized starch, povidone, sodium carboxy methyl cellulose, sodium Atorney Docket No. 047162-7542WOl(02749) alginate, citric acid, croscarmellose sodium, cellulose, carboxymethylcellulose calcium, colloidal silicone dioxide, crosspovidone and alginic acid. One or more granulating or disintegrating agents can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more granulating or disintegrating agents can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%. 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0262] Suitable binding agents include, but are not limited to, gelatin, acacia, pre-gelatinized maize starch, polyvinylpyrrolidone, anhydrous lactose, lactose monohydrate, hydroxypropyl methylcellulose, methylcellulose, povidone, polyacrylamides, sucrose, dextrose, maltose, gelatin, polyethylene glycol. One or more binding agents can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more binding agents can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%. 3%, 4%. 5%. 10%. 15%. 20%. 25%. 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0263] Suitable lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, hydrogenated castor oil, glyceryl monostearate, glyceryl behenate, mineral oil. polyethylene glycol, poloxamer 407, poloxamer 188, sodium laureth sulfate, sodium benzoate, stearic acid, sodium stearyl fumarate, silica, and talc. One or more lubricating agents can each be individually present in the composition in an amount of about 0.01% w / w to about 90% w / w relative to weight of the dosage form. One or more lubricating agents can each be individually present in the composition in an amount of at least, greater than, or less than about 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% w / w relative to weight of the dosage form.

[0264] Tablets can be non-coated or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the active ingredient. By way of example, a material such as glycery l monostearate or glyceryl distearate may be used to coat tablets. Further by way of example, tablets may be coated using methods described in U.S. Patent Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotically controlled release tablets. Tablets may further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some Atorney Docket No. 047162-7542WOl(02749) combination of these in order to provide for pharmaceutically elegant and palatable preparation.

[0265] Tablets can also be enterically coated such that the coating begins to dissolve at a certain pH, such as at about pH 5.0 to about pH 7.5, thereby releasing a compound as described herein. The coating can contain, for example, EUDRAGIT ® L, S, FS, and / or E polymers with acidic or alkaline groups to allow release of a compound as described herein in a particular location, including in any desired section(s) of the intestine. The coating can also contain, for example, EUDRAGIT ® RL and / or RS polymers with cationic or neutral groups to allow for time controlled release of a compound as described herein by pH-independent swelling.

[0266] Parenteral Administration

[0267] For parenteral administration, the compounds as described herein may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose and / or continuous infusion. Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing and / or dispersing agents may be used.

[0268] Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example as a solution in 1 , 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di -glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their poly oxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as such as lauryl, stearyl, or oleyl alcohols, or similar alcohol.

[0269] Additional Administration Forms

[0270] Additional dosage forms suitable for use with the compound(s) and compositions described herein include dosage forms as described in U.S. Patents Nos. 6.340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms Atorney Docket No. 047162-7542WOl(02749) suitable for use with the compound(s) and compositions described herein also include dosage forms as described in U.S. Patent Applications Nos. 20030147952; 20030104062;

[0271] 20030104053; 20030044466; 20030039688; and 20020051820. Additional dosage forms suitable for use with the compound(s) and compositions described herein also include dosage forms as described in PCT Applications Nos. WO 03 / 35041; WO 03 / 35040; WO 03 / 35029; WO 03 / 35177; WO 03 / 35039; WO 02 / 96404; WO 02 / 32416; WO 01 / 97783; WO 01 / 56544; WO 01 / 32217; WO 98 / 55107; WO 98 / 1 1879; WO 97 / 47285; WO 93 / 18755; and WO 90 / 11757.

[0272] Methods

[0273] In certain embodiments, the present disclosure provides a method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a human subject in need thereof. In some embodiments, the method comprises administering to the human subject: i) a pharmaceutical composition comprising a dose of 0.005 mg / kg to 0. 10 mg / kg or

[0274] 0.2 mg / kg to 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a dose of 0.0001 mg / kg to 0.9 mg / kg or

[0275] 1.1 mg / kg to 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms.

[0276] In some embodiments, the AARA is guanfacine and the dose of guanfacine is 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 1 mg / kg.

[0277] In some embodiments, the dose of guanfacine is 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg. 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg. 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0278] In some embodiments, the dose of guanfacine is greater than 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg. 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg. Atorney Docket No. 047162-7542WOl(02749)

[0279] 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0280] In some embodiments, the dose of guanfacine is lower than 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg. 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0281] In some embodiments, the dose of guanfacine is 0.005 mg / kg to 0.09 mg / kg, 0.006 mg / kg to 0.08 mg / kg, 0.005 mg / kg to 0.05 mg / kg, 0.01 mg / kg to 0.09 mg / kg, 0.008 mg / kg to 0.08 mg / kg, 0.01 mg / kg to 0.09 mg / kg, 0.2 mg / kg to 0.5 mg / kg, 0.2 mg / kg to 0.4 mg / kg, 0.3 mg / kg to 0.5 mg / kg, 0.25 mg / kg to 0.45 mg / kg, or 0.2 mg / kg to 0.3 mg / kg.

[0282] In some embodiments, the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg to 0.9 mg / kg or 1.1 mg / kg to 5 mg / kg.

[0283] In some embodiments, the dose of the psilocybin is 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg, 2.5 mg / kg, 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg, 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg. 4.75 mg / kg, or 5 mg / kg.

[0284] In some embodiments, the dose of the psilocybin is greater than 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg. 2.5 mg / kg. 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg, 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg, 4.75 mg / kg, or 5 mg / kg.

[0285] In some embodiments, the dose of the psilocybin is lower than 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg. 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg. 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg, 2.5 mg / kg, 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg, 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg, 4.75 mg / kg, or 5 mg / kg. Atorney Docket No. 047162-7542WOl(02749)

[0286] In some embodiments, the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg to 0.5 mg / kg, 0.02 mg / kg to 0.4 mg / kg, 0.05 mg / kg to 0.9 mg / kg. 1. 1 mg / kg to 3 mg / kg, 1.5 mg / kg to 4 mg / kg, 2 mg / kg to 5 mg / kg, or 1. 1 mg / kg to 2 mg / kg.

[0287] In certain aspects, the present disclosure also provides a method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a human subject in need thereof. In some embodiments, the method comprising: administering to the human subject: i) a pharmaceutical composition comprising a c -adrenergic receptor agonist

[0288] (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0289] In some embodiments, the pharmaceutical composition comprising the AARA is administered (i) more than 24 hours before administration of the pharmaceutical composition comprising the psychedelic agent or (ii) about 20 minutes or about 45 minutes before administration of the pharmaceutical composition comprising the psychedelic agent. In some embodiments, the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA). or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 20 mg / kg of the AARA; and ii) the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.0001 mg / kg to0.9 mg / kg or 1. 1 mg / kg to 5 mg / kg of the psychedelic agent. In some embodiments, the AARA is guanfacine and the psychedelic agent is psilocybin.

[0290] Composition

[0291] In certain aspects, the present disclosure provides a pharmaceutical composition comprising: i) a dose of 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 20 mg / kg of a a2.\-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and Atorney Docket No. 047162-7542WOl(02749) ii) a dose of 0.0001 mg / kg to 0.9 mg / kg or 1.1 mg / kg to 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0292] In some embodiments, the AARA is guanfacine and the dose of guanfacine is 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 1 mg / kg.

[0293] In some embodiments, the dose of guanfacine is 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0294] In some embodiments, the dose of guanfacine is greater than 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0295] In some embodiments, the dose of guanfacine is lower than 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg. 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0296] In some embodiments, the dose of guanfacine is 0.005 mg / kg to 0.09 mg / kg, 0.006 mg / kg to 0.08 mg / kg, 0.005 mg / kg to 0.05 mg / kg, 0.01 mg / kg to 0.09 mg / kg, 0.008 mg / kg to 0.08 mg / kg, 0.01 mg / kg to 0.09 mg / kg, 0.2 mg / kg to 0.5 mg / kg, 0.2 mg / kg to 0.4 mg / kg, 0.3 mg / kg to 0.5 mg / kg, 0.25 mg / kg to 0.45 mg / kg, or 0.2 mg / kg to 0.3 mg / kg. including all values and sub ranges in between.

[0297] In some embodiments, the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg 0.9 mg / kg or 1.1 mg / kg to 5 mg / kg.

[0298] In some embodiments, the dose of the psilocybin is 0.05 mg / kg. 0. 1 mg / kg, 0. 15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg, 2.5 mg / kg, 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg, 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg. 4.75 mg / kg, or 5 mg / kg. Atorney Docket No. 047162-7542WOl(02749)

[0299] In some embodiments, the dose of the psilocybin is greater than 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg, 2.5 mg / kg,

[0300] 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg, 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg,

[0301] 4.75 mg / kg, or 5 mg / kg.

[0302] In some embodiments, the dose of the psilocybin is lower than 0.05 mg / kg, 0. 1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, 1.25 mg / kg, 1.5 mg / kg, 1.75 mg / kg, 2 mg / kg, 2.25 mg / kg, 2.5 mg / kg,

[0303] 2.75 mg / kg, 3 mg / kg, 3.25 mg / kg. 3.5 mg / kg, 3.75 mg / kg, 4 mg / kg, 4.25 mg / kg, 4.5 mg / kg,

[0304] 4.75 mg / kg, or 5 mg / kg.

[0305] In some embodiments, the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg to 0.5 mg / kg, 0.02 mg / kg to 0.4 mg / kg, 0.05 mg / kg to 0.9 mg / kg, 1. 1 mg / kg to 3 mg / kg, 1.5 mg / kg to 4 mg / kg, 2 mg / kg to 5 mg / kg, or 1. 1 mg / kg to 2 mg / kg, including all values and sub ranges in between.

[0306] Controlled Release Formulations and Drug Delivery Systems

[0307] In certain embodiments, the formulations described herein can be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.

[0308] The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may. although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.

[0309] For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use with the method(s) described herein may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.

[0310] In some cases, the dosage forms to be used can be provided as slow or controlled- release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer Atorney Docket No. 047162-7542WOl(02749) coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations know n to those of ordinary skill in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions described herein. Thus, single unit dosage forms suitable for oral administration, such as tablets, capsules, gelcaps, and caplets, that are adapted for controlled-release are encompassed by the compositions and dosage forms described herein.

[0311] Most controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood level of the drug, and thus can affect the occurrence of side effects.

[0312] Most controlled-release formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.

[0313] Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds. The term “controlled-release component” is defined herein as a compound or compounds, including, but not limited to, polymers, polymer matrices, gels, permeable membranes, liposomes, or microspheres or a combination thereof that facilitates the controlled-release of the active ingredient. In one embodiment, the compound(s) described herein are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation. In one embodiment, the compound(s) described herein are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.

[0314] The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug Atorney Docket No. 047162-7542WOl(02749) administration and that mat, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.

[0315] The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.

[0316] The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.

[0317] As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.

[0318] As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.

[0319] Dosing

[0320] The therapeutically effective amount or dose of a compound described herein depends on the age, sex and weight of the patient, the current medical condition of the patient and the progression of PTSD or symptoms thereof in the patient being treated. The skilled artisan is able to determine appropriate dosages depending on these and other factors.

[0321] A suitable dose of a compound described herein can be in the range of from about 0.01 mg to about 5,000 mg per day, such as from about 0.1 mg to about 1,000 mg, for example, from about 1 mg to about 500 mg. such as about 5 mg to about 250 mg per day. The dose may be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage may be the same or different. For example, a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses.

[0322] It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on. Atorney Docket No. 047162-7542WOl(02749)

[0323] In the case wherein the patient’s status does improve, upon the doctor’s discretion the administration of the compound(s) described herein is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days. 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0324] Once improvement of the patient’s conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced to a level at which the improved disease is retained. In certain embodiments, patients require intermitent treatment on a long-term basis upon any recurrence of symptoms and / or infection.

[0325] The compounds described herein can be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form may be for a single daily dose or one of multiple daily doses (e.g, about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.

[0326] Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LDso (the dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LDso and EDso. The data obtained from cell culture assays and animal studies are optionally used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the EDso with minimal toxicity7. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized. Atorney Docket No. 047162-7542WOl(02749)

[0327] EXAMPLES

[0328] Various embodiments of the present application can be beter understood by reference to the following Examples which are offered by way of illustration. The scope of the present application is not limited to the Examples given herein.

[0329] Animals

[0330] All experiments used wild-type C57BL6 / J background mice purchased from Jackson laboratories at 6-8 weeks of age. Animals were group housed, kept on a l2 h / 12 h light-dark cycle, and were provided ad libitum chow and water. All experiments were performed during the light cycle (7:00-19:00).

[0331] Drug Preparation and Administration

[0332] Drugs were administered intraperitoneal (IP) at 0.01 mL / kg using insulin syringes. MDMA, psilocybin, reboxetine, and guanfacine w ere purchased from Cayman Chemicals (Ann Arbor, MI) and dissolved in saline. Yohimbine was purchased from Sigma Aldrich (St. Louis, MO) and dissolved in distilled water.

[0333] For fear conditioning studies, drug was administered 30 minutes before the start of the trail. In 5-HT and NE photometry' studies, drug was administered immediately before placing the mouse in an empty box, 5 minutes after the start of recording to get a baseline measure. For dose response curves of HTR. drug was administered immediately before the start of the trial. In the HTR and photometry that involved reboxetine and fluoxetine, these inhibitors were injected one minute before entactogen administration. Guanfacine was injected 15 minutes before reboxetine or psilocybin administration. Y ohimbine was administered 2 minutes before MDMA administration in HTR studies.

[0334] Surgeries

[0335] For all stereotaxic surgical procedures, mice w ere first anesthetized with isoflurane in oxy gen (3-5% during induction, slowly lowered throughout the surgery to 1-2%) while placed in a stereotaxic apparatus (Stoelting). Eyes were lubricated with ophthalmic ointment. Hair was removed with scissors or an electric razor (Phillips), and an incision in the scalp w as made to expose the skull. A craniotomy was then made with either a rotary tool (Dremel) or a dental drill above the mPFC. 0.5 pL of AAV9-hSyn-NE2h (WZ Biosciences) virus (1 x 1013genome copies per mL) was then loaded into a Hamilton syringe. The tip of the syringe was then placed over the craniotomy and then lowered to the injection site. Injections were targeted to the prefrontal cortex (AP: +1.6-2.1 mm AP, ML: ±0.3 mm, DV: Atorney Docket No. 047162-7542WOl(02749)

[0336] 1.3 mm below dura). Virus was then injected at a rate of 0. 1 pL / min. After injection, the syringe was left in place for at least 5 minutes, then slowly raised out of the craniotomy. Fiber implantation was done directly after virus injection. Fiber optic implants (0.2 mm core. Neurophotometrics) were cut to 3 mm length. Implants were held in the stereotaxic apparatus and lowered to the viral injection coordinates. Implants were then secured with quick adhesive cement (C&B Metabond, Parked). Mice were then removed from the apparatus and recovered in the home cage. All mice received carprofen (5 mg / kg, Zoetis) intraperitoneally after surgery and for two days following surgery. Any behavioral testing took place at least 3 weeks after surgery7.

[0337] Fiber Photometry

[0338] Mice used in fiber photometry experiments were subjected to the surgical procedures described herein approximately 4-8 weeks prior to experimental sessions. A crossover design was used for these experiments, in which each animal received all drug conditions over the course of several days (one day between each condition). The cohort of animals used to measure 5-HT received MDMA (12 mg / kg) and saline. The cohort for NE received MDMA (12 mg / kg) and saline. The NE blocker photometry studies with fluoxetine and reboxetine were done with the cohort from the NE study, with all animals receiving fluoxetine (10 mg / kg) + MDMA (12 mg / kg) and reboxetine (10 mg / kg) + MDMA (12 mg / kg) over two experimental sessions with one day between them. In this case, when animals were used in two photometry studies, the cohort was run at least 2 weeks after the end of the first experiment.

[0339] Fiber photometry7of sensor fluorescence was performed using an FP3002 fiber photometry system (Neurophotometrics). A fiber optic cable (Doric) connected to the FP3002 was atached to fiber optic implants via a ceramic sleeve. Light at the excitation wavelength (470 nm) and an isosbestic control wavelength (415 nm) was produced from LEDs and propagated through the fiber optic cable to the fiber optic implant. Emission light from the fluorescent sensor was then captured using an sCMOS camera. Excitation wavelengths were used at 10% power, and 470 nm and 415 nm excitation was interleaved at a total sampling rate of 40 Hz, producing 20 Hz recordings for each channel. Only analysis using the 470 nm excitation channel w as performed, since 415 nm is not a true isosbestic point for GRABNE.

[0340] Recordings were saved and analyzed offline. For each recording, the injection fluorescence change was calculated as a percent change from the pre-inj ection average. Fluorescence from the 470 nm channel was extracted from 120 s-240 s and used as a Atorney Docket No. 047162-7542WOl(02749) baseline. The percent change for each trial was calculated as a percent change from the average signal from 120 s to 240 s after the beginning of the recording before drug administration: that is, dF / F = ((signal) - (average signal from 120 s to 240 s after onset of recording)) / (average signal from 120 s to 240 s after onset recording). Analyses were performed using custom MATLAB scripts, and statistical analysis were performed using MATLAB or GraphPad Prism 9.

[0341] Head Twitch Response

[0342] Head twitch response (HTR) was evaluated using C57BL / 6J mice (ages 7-12 weeks). Mice were ear tagged >3 days after arrival to the animal facility and allowed to rest for at least 3 days before behavioral testing. Small magnets (SuperMagnetMan - N45 magnet 3 mm diameter, 0.5 mm thickness) were glued to ear tags (Stoelting - La Pias Aluminum Ear Tags) >2 days before mice were ear tagged. The experimental setup was adapted from Gonzales-Maeso and Kwan, including experimental apparatus and Matlab code for analysis.

[0343] Doses were randomly assigned, and age matched controls were injected with saline and randomly interspersed with drug conditions. At least three animals per sex were used for each drug dose and condition. In the event that animals were used in more than one HTR experiment, experimental sessions took place at least one week apart. Two animals were run at a time. Immediately after i.p. injection of psychedelic or entactogen drug, animals were placed in separate plastic boxes within a larger chamber (Home Depot - 28 in. W x 32 in. H x 21.5 in. D), and HTR was measured for 10 minutes for dose response curves, and 30 minutes for other circuit level HTR experiments (FIGs. 2A-2C, 3A-3C, and 4A-4C). A small lamp was placed in the back of the larger chamber, and a high-speed camera (Basler - acA1920- 155um) was suspended from the ceiling to record video of the animals in the plastic boxes. Between each recording, the plastic boxes were cleaned with 70% ethanol. Head twitch counts were imported into Prism and used to make graphs and run appropriate statistics for analysis.

[0344] Example 2: Combination therapy of guanfacine and psilocybin

[0345] This example provides combined therapy of psilocybin with guanfacine — an FDA- approved a2-adrenergic receptor agonist with an established safety profile. At the dose tested (0.15 mg / kg), guanfacine significantly reduced psilocybin-induced head twitch response (HTR) — a rodent correlate of 5-HT2A-mediated hallucinogenic activity' — without affecting locomotor activity, indicating a selective attenuation of hallucinogenic-like effects. This example evaluates whether this combination preserved the therapeutic efficacy of psilocybin Atorney Docket No. 047162-7542WOl(02749) in a validated chronic multimodal stress (CMMS) model in mice. Behavioral outcomes were assessed across multiple domains, including behavioral despair (forced swim test) and anhedonia (sucrose preference test).

[0346] The results suggest that the guanfacine-psilocybin combination retains antidepressantdike properties while significantly reducing hallucinogenic-like responses, supporting the feasibility of a safer and more scalable psychedelic therapy.

[0347] Methods

[0348] Animals and housing

[0349] Male C57BL / 6J mice (8-12 weeks old on arrival) were used across all experiments. Upon arrival, animals were group-housed for 7 days under standard laboratory conditions (22 ± 1°C, 12: 12 light / dark cycle, 50-60% humidity, with ad libitum access to food and water). Housing modifications (e.g., transition to single housing) were introduced only when required by specific protocols, as described in the relevant sections herein.

[0350] Head twitch response (HTR)

[0351] HTR was used to quantify 5-HT2A receptor-mediated hallucinogenic-like activity. Mice were ear-tagged using aluminum ear tags (Stoelting) and fited with small neodymium magnets (SuperMagnetMan N45, 3 mm diameter x 0.5 mm thickness) at least 48 hours prior to testing.

[0352] Two experimental designs were used. In the first, a fixed dose of psilocybin (1 mg / kg) was administered following pretreatment with increasing doses of guanfacine (0.015, 0.05, 0.15, or 0.5 mg / kg). This design allowed assessment of the dose-dependent effects of guanfacine on psilocybin-induced HTR. In the second, mice received intraperitoneal injections of psilocybin at 0.3, 1, or 3 mg / kg, either alone or 15 minutes after guanfacine (0. 15 mg / kg), to test whether guanfacine atenuates the HTR across a range of psilocybin doses.

[0353] In both experiments, HTR was recorded for 30 minutes immediately after psilocy bin injection. Mice were placed into individual clear plastic enclosures housed within a larger chamber (28" W x 32" H x 21.5" D), and behavior was recorded using a ceiling-mounted high-speed camera (Basler Acal920-155 pm). HTR events were detected using a magnetometer-based signal analysis system and confirmed by automated MATLAB analysis adapted from Jefferson et al., 2023 (5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. 2023 Aug; 48(9): 1257- Atorney Docket No. 047162-7542WOl(02749)

[0354] 1266). Enclosures were cleaned with 70% ethanol between trials. All injections were carried out in a volume of 10 mL / kg of body weight.

[0355] Locomotor Activity

[0356] To evaluate whether guanfacine affected general behavioral activity' levels, mice were tested in a home-cage infrared beam-based system (Med Associates Inc.). After a 1-hour habituation to the testing room, animals were individually placed into clean, bedding-free standard cages positioned within a 16-beam photobeam grid. Locomotor activity was recorded for 60 minutes prior to drug injection and for an additional 60 minutes following guanfacine or saline administration. Guanfacine was delivered intraperitoneally at doses of 0.015, 0. 15, or 0.5 mg / kg in a volume of 10 mL / kg body weight in sterile saline. Chronic Multimodal Stress (CMMS)

[0357] On Day 1 of the CMMS protocol — eight days after arrival — mice were transferred from group to single housing to allow for individual fluid intake monitoring during behavioral testing. That same evening, they were habituated overnight to a two-botle choice setup with access to 1.5% sucrose and water. On Days 2 and 3 of the CMMS protocol, baseline sucrose preference was assessed using freshly prepared 1% sucrose solution. Each session lasted 14 hours and was conducted during the dark phase of the light / dark cycle. Botle positions were alternated to control for side bias, and intake was measured by weight before and after testing. On Day 4 of the CMMS protocol, mice began 15 consecutive days of stress consisting of 5-hour restraint sessions in ventilated 50 ml Falcon tubes. Stress sessions were conducted in a dedicated room equipped with 2 Hz strobe lighting and 75 dB white noise to prevent habituation. The timing of each session varied daily to increase unpredictability'. After each session, animals were returned to their home cages. On Days 18 and 19. sucrose preference was reassessed using the same procedure employed at baseline to evaluate stress-induced anhedonia. The protocol was adapted with minor modifications from Hesselgrave et al., 2021 (Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2022489118. doi: 10. 1073 / pnas.2022489118. PMID: 33850049; PMCID: PMC8092378 ).

[0358] Sucrose Preference Test (SPT)

[0359] Sucrose preference was calculated as [sucrose intake / (sucrose + water intake)] x 100. A 1.5% sucrose solution was used during the initial habituation phase, and a 1% sucrose solution was used for all baseline, post-stress, and post-treatment testing. Botles were Atorney Docket No. 047162-7542WOl(02749) weighed before and after each session, and positions were alternated to control for side preference.

[0360] Tail Suspension Test (TST)

[0361] The day following the final stress session, animals were tested in the TST to assess behavioral despair prior to pharmacological treatment. Mice were suspended by the tail using adhesive tape affixed approximately 1 cm from the tail tip and hung from a straight 10 cm horizontal metal bar mounted to a stable frame. Each session lasted 6 minutes and was video recorded. Immobility was scored manually during the first 5 minutes of the test. Immobility was defined as the absence of any active movement. Animals were tested in a quiet room under consistent lighting conditions to minimize external stimuli.

[0362] Pharmacological Treatments post-stress

[0363] Following TST, animals were stratified into three groups based on SPT and TST scores: (1) Saline-Saline, (2) Saline-Psilocybin (1 mg / kg), and (3) Guanfacine (0.15 mg / kg)- Psilocybin (1 mg / kg). Treatments were administered intraperitoneally in sterile 0.9% saline (10 mL / kg), with a 15-minute interval between guanfacine and psilocybin. All injections were carried out in a volume of 10 mL / kg of body weight. Post-Treatment SPT

[0364] Four hours after the final injection, mice remained in their home cages and were exposed to a 14-hour overnight sucrose preference test using a 1% sucrose solution. Bottle positions were alternated, and intake was measured by weight before and after the session. Forced Swim Test (FST)

[0365] On Day 21 of the CMMS protocol (24 hours after pharmacological treatment), mice were tested in the FST to assess despair-like behavior. Animals were individually placed in a cylindrical glass beaker (20 cm diameter) filled with water maintained at 21 ± 1°C to a depth of 15 cm. Each session lasted 6 minutes and was video recorded with a camera. Immobility — defined as floating with minimal movements necessary to keep the head above water — was scored manually during minutes 2 through 6. All animals were tested under uniform environmental conditions. Between trials, beakers were emptied, cleaned, and refilled with fresh water to avoid potential olfactory cues.

[0366] Results

[0367] Psilocybin-Induced Head Twitch Response (HTR) Are Diminished by Guanfacine

[0368] Methods: Atorney Docket No. 047162-7542WOl(02749)

[0369] Two HTR experiments were conducted. In the first, mice received psilocybin (1 mg / kg, i.p.) following pretreatment with increasing doses of guanfacine (0.015, 0.05, 0.15. or 0.5 mg / kg, i.p.). In the second, mice were treated with psilocybin at 0.3, 1, or 3 mg / kg, either alone or 15 minutes after guanfacine (0. 15 mg / kg). HTRs were recorded over 30 minutes using a magnetometer-based system. Results:

[0370] As shown in FIGs. 6A, 6B, and 7, guanfacine significantly suppressed psilocybin- induced HTR in a dose-dependent manner. At 0. 15 mg / kg, guanfacine effectively reduced HTR across all tested psilocybin doses.

[0371] FIGs. 6A-6B are dose-response curve of psilocybin-induced HTR. FIG. 6A depicts total number of HTR over 30 minutes after administration of psilocybin (0.3 mg / kg, 1 mg / kg, or 3 mg / kg) with saline or 0. 15 mg / kg guanfacine pretreatment. One line represents psilocybin alone; the other line represents psilocybin administered 15 minutes after guanfacine. Error bars represent the mean ± S.E.M. Guanfacine pretreatment atenuated HTR across all tested doses of psilocybin, (n = 5-7 per group). FIG. 6B shows HTR with pretreatment of 0. 15 mg / kg guanfacine as percent reduction in HTR with saline pretreatment. Relative percent suppression in psilocybin-induced HTR by guanfacine was calculated as the percentage change induced by guanfacine pre-treatment as compared with saline- pretreatment before that dose of psilocybin.

[0372] FIG. 7 illustrates Head Twitch Response (HTR) measured over 30 minutes following psilocybin (1 mg / kg, i.p.) with or without guanfacine pretreatment. Guanfacine was administered at 0.015, 0.05, 0.15, or 0.5 mg / kg (i.p.) 15 minutes prior to psilocybin. Individual values are represented as dots, with error bars indicating the mean ± S.E.M. Guanfacine dose-dependently reduced psilocybin-induced HTR. Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparisons test (****P < 0.0001). The results demonstrate that the effect is dose-dependent, occurring at a dosage which approximates typically used guanfacine dosages equivalent to those used in humans. In addition, the results demonstrate that guanfacine's suppression of head twitch is observed across a range of doses, and the reduction of head twitch is monotonic, in accordance of various embodiments.

[0373] These results demonstrate that guanfacine atenuates the 5-HT2A receptor-mediated hallucinogenic-like response evoked by psilocybin, supporting its role in non-hallucinogenic psychedelic therapy development. Atorney Docket No. 047162-7542WOl(02749)

[0374] Chronic Stress Paradigm - Behavioral Effects (Forced Swim Test and Sucrose Preference Test)

[0375] Methods:

[0376] Mice were subjected to 15 days of chronic multimodal stress (CMMS). Post-stress, animals were divided into three balanced groups based on Tail Suspension Test (TST) and Sucrose Preference Test (SPT) performance:

[0377] (1) Saline-Saline,

[0378] (2) Saline-Psilocybin (1 mg / kg, intraperitoneal), and

[0379] (3) Guanfacine (0.15 mg / kg, intraperitoneal) - Psilocybin (1 mg / kg, intraperitoneal, 15 minutes later).

[0380] • FST was performed 24 hours after treatment to assess despair-like behavior.

[0381] • SPT was conducted 4 hours after treatment as a 14-hour overnight session to evaluate anhedonia.

[0382] Results:

[0383] • Sucrose Preference Test (SPT):

[0384] In the Saline-Saline group, sucrose preference significantly declined from baseline to post-stress and remained low after treatment (Friedman test, P = 0.0017).

[0385] In the Psilocybin group, sucrose preference dropped after stress and was significantly improved by treatment (repeated measures ANOVA, P < 0.0001; post hoc P = 0.0121 for post-stress vs post-treatment), though not fully restored to baseline.

[0386] In the Guanfacine-Psilocybin group, a similar stress-induced reduction was observed (Friedman test, P < 0.0001), and while post-treatment levels increased (baseline vs posttreatment P = 0.0216), the change from post-stress was not significant (P = 0.2460), indicating only partial recovery. The results are displayed in FIG. 8B.

[0387] • Forced Swim Test (FST):

[0388] Immobility time differed significantly across groups (one-way ANOVA, P = 0.0033). Both Psilocybin (P = 0.0039) and Guanfacine-Psilocybin (P = 0.0107) groups showed significantly reduced immobility time compared to Saline-Saline, supporting robust antidepressant-like effects, as shown in FIG. 8C.

[0389] Conclusions:

[0390] Co-administration with guanfacine maintains psilocybin’s antidepressant-like effect in despair-related behavior, but may partially blunt the pro-hedonic effects observed in the SPT. Atorney Docket No. 047162-7542WOl(02749)

[0391] Locomotor Activity (Open Field Test)

[0392] Methods:

[0393] Mice received intraperitoneal injections of guanfacine at 0.015, 0. 15, or 0.5 mg / kg. Locomotor activity’ was assessed in a beam-break open field system by measuring total distance traveled during the 60 minutes following drug administration.

[0394] Results:

[0395] FIG. 9 shows the total distance traveled across treatment groups. There were no significant differences in locomotor activity following guanfacine administration (one-way ANOVA, F = 0.4647, P = 0.7097), indicating that guanfacine did not impact spontaneous movement at any of the tested doses.

[0396] Guanfacine was behaviorally neutral in the open field test and did not induce sedation or hyperactivity, supporting the interpretation that its effects on Head Twitch Response outcomes were not confounded by changes in baseline locomotion.

[0397] The terms and expressions employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible w ithin the scope of the embodiments of the present application. Thus, it should be understood that although the present application describes specific embodiments and optional features, modification and variation of the compositions, methods, and concepts herein disclosed may be resorted to by those of ordinary' skill in the art, and that such modifications and variations are considered to be within the scope of embodiments of the present application.

[0398] Enumerated Embodiments

[0399] The following enumerated embodiments are provided, the numbering of which is not to be construed as designating levels of importance:

[0400] Embodiment 1 : A method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a subject in need thereof, the method comprising: administering to the subject: i) a pharmaceutical composition comprising a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and Atorney Docket No. 047162-7542WOl(02749) ii) a pharmaceutical composition comprising a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0401] Embodiment 2: The method of embodiment 1, wherein the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz. guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0402] Embodiment 3: The method of embodiment 1, wherein the psychedelic agent comprises psilocybin, 2C-B (4-bromo-2,5-dimethoxyphenethylamine), ketamine, tryptamine, a tryptamine derivative, DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy- dimethyltryptamine), 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine), LSA (d- lysergic acid amide), LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0403] Embodiment 4: The method of embodiment 1, wherein the AARA is guanfacine and the dose of guanfacine is about 0.005 mg / kg to about 0.10 mg / kg or about 0.2 mg / kg to about 1 mg / kg.

[0404] Embodiment 5: The method of embodiment 4, wherein the dose of guanfacine is about 0.005 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.025 mg / kg, about 0.03 mg / kg, about 0.035 mg / kg, about 0.04 mg / kg, about 0.045 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg.

[0405] Embodiment 6: The method of embodiment 1, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg. Atorney Docket No. 047162-7542WOl(02749)

[0406] Embodiment 7 : The method of embodiment 6, wherein the dose of the psilocybin is about 0.01 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.15 mg / kg. about 0.2 mg / kg, about 0.25 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 1.25 mg / kg, or about 1.5 mg / kg.

[0407] Embodiment 8: The method of embodiment 1, wherein the subject is administered about 1 to about 1000 mg of the AARA.

[0408] Embodiment 9: The method of embodiment 1, wherein the subject is administered about 1 to about 1000 mg of the psychedelic agent.

[0409] Embodiment 10: The method of embodiment 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as separate dosage forms.

[0410] Embodiment 11 : The method of embodiment 10, wherein the pharmaceutical composition comprising the AARA is administered to the subject about 1 minute to about 24 hours before the pharmaceutical composition comprising the psychedelic agent is administered to the subject.

[0411] Embodiment 12: The method of embodiment 1, wherein the pharmaceutical composition comprising the AARA is administered to the subject separately and / or at a different time from the pharmaceutical composition comprising the psychedelic agent.

[0412] Embodiment 13: The method of embodiment 1. wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are administered concurrently.

[0413] Embodiment 14: The method of embodiment 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

[0414] Embodiment 15: The method of embodiment 1, wherein the single dosage form comprises an anti-abuse formulation.

[0415] Embodiment 16: The method of embodiment 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are independently administered by a route independently selected from the group consisting of transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalational. and topical administration. Atorney Docket No. 047162-7542WOl(02749)

[0416] Embodiment 17: The method of embodiment 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent each independently further comprise at least one pharmaceutically acceptable carrier or excipient.

[0417] Embodiment 18: A method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a human subject in need thereof, the method comprising: administering to the human subject: i) a pharmaceutical composition comprising a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA is administered (i) more than 24 hours before administration of the pharmaceutical composition comprising the psychedelic agent or (ii) about 20 minutes or about 45 minutes before administration of the pharmaceutical composition comprising the psychedelic agent; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0418] Embodiment 19: The method of embodiment 18, wherein i) the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of the AARA; and ii) the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of the psychedelic agent.

[0419] Embodiment 20: The method of embodiment 18 or 19, wherein the AARA is guanfacine and the psychedelic agent is psilocybin.

[0420] Embodiment 21: A pharmaceutical composition comprising: Atorney Docket No. 047162-7542WOl(02749) i) a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0421] Embodiment 22: The pharmaceutical composition of embodiment 21, wherein the AARA is guanfacine and the dose of guanfacine is about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 1 mg / kg.

[0422] Embodiment 23: The pharmaceutical composition of embodiment 22, wherein the dose of guanfacine is about 0.005 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg. about 0.025 mg / kg, about 0.03 mg / kg, about 0.035 mg / kg, about 0.04 mg / kg, about 0.045 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg.

[0423] Embodiment 24: The pharmaceutical composition of any one of embodiments 21-23, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg.

[0424] Embodiment 25: The pharmaceutical composition of embodiment 24, wherein the dose of the psilocybin is about 0.01 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 1.25 mg / kg, or about 1.5 mg / kg.

[0425] Embodiment 26: A pharmaceutical composition comprising: i) a dose of about 0.015 mg / kg, about 0.05 mg / kg or about 0.5 mg / kg of a a2A- adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a dose of about 1 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0426] Embodiment 27 : A pharmaceutical composition comprising: Atorney Docket No. 047162-7542WOl(02749) i) a dose of about 0. 15 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a dose of about 0.3 mg / kg or about 3 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0427] Embodiment 28: The pharmaceutical composition of embodiment 26 or 27, wherein the psychedelic agent comprises psilocybin, 2C-B (4-bromo-2,5-dimethoxyphenethylamine), ketamine, try ptamine, a tryptamine derivative, DMT (N,N-dimethyltryptamine), 5-MeO- DMT (5-methoxy-dimethyltryptamine), 5-MeO-MiPT (5-methoxy-N-methyl-N- isopropyltryptamine), LSA (d-lysergic acid amide), LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0428] Embodiment 29: The pharmaceutical composition of any one of embodiments 26-28, wherein the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz. guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0429] Embodiment 30: A method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof, the method comprising the pharmaceutical composition of any one of embodiments 21-29.

[0430] Embodiment 31 : The method of any one of embodiments 1 -3, 8-20, and 30, wherein the dose of the AARA is about 0.005 mg / kg to about 1 mg / kg.

[0431] Embodiment 32: The method of embodiment 31, wherein the dose of the AARA is about 0.01 mg / kg to about 0.1 mg / kg.

[0432] Embodiment 33: The method of any one of embodiments 1-3, 8-20, and 30, wherein the dose of the psychedelic agent is about 0.01 mg / kg to about 5 mg / kg.

[0433] Embodiment 34: The method of embodiment 33, wherein the dose of the psychedelic agent is about 0. 1 mg / kg to about 1 mg / kg.

[0434] Embodiment 35: The method of any one of embodiments 1-9, 18-20, and 30-34, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

[0435] Embodiment 36: The method of embodiment 35, wherein the single dosage form is a tablet or a capsule. Atorney Docket No. 047162-7542WOl(02749)

[0436] Embodiment 37: The method of embodiment 35 or 36, wherein the pharmaceutical composition comprising the AARA is formulated as an immediate release component.

[0437] Embodiment 38: The method of embodiment 35 or 36, wherein the pharmaceutical composition comprising the AARA is formulated as a delayed release component.

[0438] Embodiment 39: The method of any one of embodiments 35-38, wherein the pharmaceutical composition comprising the psychedelic agent is formulated as an immediate release component.

[0439] Embodiment 40: The method of any one of embodiments 35-38, wherein the pharmaceutical composition comprising the psychedelic agent is formulated as a delayed release component.

[0440] Embodiment 41 : The method of any one of embodiments 1-20 and 30-40, wherein the AARA is guanfacine, wherein the psychedelic agent is psilocybin, and wherein the guanfacine and the psilocybin are the only therapeutically effective agents administered to the subject.

[0441] Embodiment 42: The pharmaceutical composition of any one of embodiments 21-29, wherein the AARA is guanfacine, wherein the psychedelic agent is psilocybin, and wherein the guanfacine and the psilocybin are the only therapeutically effective agents present in the pharmaceutical composition.

[0442] Embodiment 1 A provides a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof, the method comprising: administering to the subject: i) a pharmaceutical composition comprising a therapeutically effective amount of a norepinephrine inhibitor (NEI), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a therapeutically effective amount of an entactogen, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are formulated as a single dosage form or as separate dosage forms; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0443] Embodiment 2 A provides the method of embodiment 1A. wherein the NEI is selected from the group consisting of atomoxetine ((7?)-A-methyl-3-phenyl-3-(o-tolyloxy)propan-l- Atorney Docket No. 047162-7542WOl(02749) amine), reboxetine (re / -(27?)-2-[(J?)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine), viloxazine ((7t’)-2-[(2-ethoxyphenoxy)methyl]morpholine), amedalin (UK-3540-1), daledalin (UK-3557-15), edivoxetine (LY-2216684), esreboxetine (AXS-14; PNU-165442G), lortalamine (LM-1404), nisoxetine (LY-94,939), talopram (tasulopram) (Lu 3-010), talsupram (Lu 5-005), and tandamine (AY-23,946), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0444] Embodiment 3AA provides the method of embodiment 1A, wherein the entactogen is selected from the group consisting of MDMA (3,4-methylenedioxymethamphetamine), MDA (3 ,4-methylenedi oxy amphetamine), MDE A (3.4-methy I enedi oxy- A-ethy lamphetamine), MDOH (3,4-methylenedioxy-N-hydroxyamphetamine). MBDB ( 1 ,3-benzodioxolyl-A- methylbutanamine), 5-APB (l-benzofuran-5-ylpropan-2-amine), 5-MAPB (l-(benzofuran-5- yl)-A-methylpropan-2-amine), 6-APB (6-(2-aminopropyl)benzofuran), 6-MAPB (1- (benzofuran-6-yl)-7V-methylpropan-2-amine), methylone (3,4-methylenedioxy-N- methylcathinone), mephedrone (4-methylmethcathinone), GHB (y-hydroxybutyric acid), aMT (a-methyltryptamine), aET (a-ethyltryptamine). and MDAI (5,6-methylenedioxy-2- aminoindane), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0445] Embodiment 4A provides the method of any one of embodiments 1 A-3A, wherein the NEI is reboxetine.

[0446] Embodiment 5 A provides the method of any one of embodiments 1A-4A, wherein the entactogen is MDMA.

[0447] Embodiment 6A provides the method of any one of embodiments 1 A-5A, wherein the subject is administered about 1 to about 1000 mg of the NEL

[0448] Embodiment 7 A provides the method of any one of embodiments 1 A-6A, wherein the subject is administered about 1 to about 1000 mg of the entactogen.

[0449] Embodiment 8A provides the method of any one of embodiments 1 A-7A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are formulated as separate dosage forms.

[0450] Embodiment 9A provides the method of any one of embodiments 1 A-8 A, wherein the pharmaceutical composition comprising the NEI is administered to the subject about 1 minute to about 24 hours before the pharmaceutical composition comprising the entactogen is administered to the subject. Atorney Docket No. 047162-7542WOl(02749)

[0451] Embodiment 10A provides the method of any one of embodiments 1A-9A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are administered concurrently.

[0452] Embodiment 11 A provides the method of any one of embodiments 1A-10A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are formulated as a single dosage form.

[0453] Embodiment 12A provides the method of any one of embodiments 1A-11A, wherein the single dosage form comprises an anti-abuse formulation.

[0454] Embodiment 13A provides the method of any one of embodiments 1A-12A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen are independently administered by a route independently selected from the group consisting of oral transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0455] Embodiment 14A provides the method of any one of embodiments 1A-13A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen each independently further comprise at least one pharmaceutically acceptable carrier or excipient.

[0456] Embodiment 15A provides a method of treating, ameliorating, or preventing post- traumatic stress disorder in a subject in need thereof, the method comprising: administering to the subject: i) a pharmaceutical composition comprising a therapeutically effective amount of a ot2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a therapeutically effective amount of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented. Atorney Docket No. 047162-7542WOl(02749)

[0457] Embodiment 16A provides the method of any embodiment 15 A, wherein the AARA is selected from the group consisting of clonidine. dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, and lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0458] Embodiment 17A provides the method of any one of embodiments 15A-16A, wherein the psychedelic agent is selected from the group consisting of psilocybin, 2C-B (4-bromo- 2,5-dimethoxyphenethylamine), ketamine, DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-dimethyltyptamine), LSA (d-lysergic acid amide), and LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0459] Embodiment 18A provides the method of any one of embodiments 15A-17A, wherein the AARA is guanfacine.

[0460] Embodiment 19A provides the method of any one of embodiments 15A-18A, wherein the psychedelic agent is psilocybin.

[0461] Embodiment 20 A provides the method of any one of embodiments 15A-19A, wherein the subject is administered about 1 to about 1000 mg of the AARA.

[0462] Embodiment 21 A provides the method of any one of embodiments 15A-20A, wherein the subject is administered about 1 to about 1000 mg of the psychedelic agent.

[0463] Embodiment 22A provides the method of any one of embodiments 15A-21A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as separate dosage forms.

[0464] Embodiment 23 A provides the method of any one of embodiments 15A-22A. wherein the pharmaceutical composition comprising the AARA is administered to the subject about 1 minute to about 24 hours before the pharmaceutical composition comprising the psychedelic agent is administered to the subject.

[0465] Embodiment 24A provides the method of any one of embodiments 15A-23A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are administered concurrently.

[0466] Embodiment 25 A provides the method of any one of embodiments 15A-24A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

[0467] Embodiment 26A provides the method of any one of embodiments 15A-25A, wherein the single dosage form comprises an anti-abuse formulation. Atorney Docket No. 047162-7542WOl(02749)

[0468] Embodiment 27A provides the method of any one of embodiments 15A-26A. wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are independently administered by a route independently selected from the group consisting of oral transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0469] Embodiment 28A provides the method of any one of embodiments 15A-27A, wherein the pharmaceutical composition comprising the NEI and the pharmaceutical composition comprising the entactogen each independently further comprise at least one pharmaceutically acceptable carrier or excipient.

[0470] Embodiment 29 A provides a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a subject in need thereof, the method comprising: administering to the subject: i) a pharmaceutical composition comprising a dose of 0.005 mg / kg 0. 10 mg / kg or 0.2 mg / kg to 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a dose of 0.0001 mg / kg to 0.9 mg / kg or

[0471] 1.1 mg / kg to 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0472] Embodiment 30A provides the method of embodiment 29 A, wherein the AARA is selected from the group consisting of clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, and lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0473] Embodiment 31 A provides the method of any one of embodiments 29A-30A, wherein the psychedelic agent is selected from the group consisting of psilocybin. 2C-B (4-bromo- 2,5-dimethoxyphenethylamine), ketamine, DMT (N,N-dimethyltryptamine), 5-MeO-DMT Atorney Docket No. 047162-7542WOl(02749)

[0474] (5-methoxy-dimethyltyptamine), LSA (d-lysergic acid amide), and LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0475] Embodiment 32 A provides the method of any one of embodiments 29A-31A, wherein the AARA is guanfacine and the dose of guanfacine is 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 1 mg / kg.

[0476] Embodiment 33A provides the method of any one of embodiments 29A-32A, wherein the dose of guanfacine is 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg. or 1 mg / kg.

[0477] Embodiment 34 A provides the method of any one of embodiments 29A-33A, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg to 0.9 mg / kg or 1.1 mg / kg to 1.5 mg / kg.

[0478] Embodiment 35A provides the method of any one of embodiments 29A-34A, wherein the dose of the psilocybin is 0.01 mg / kg, 0.05 mg / kg, 0. 1 mg / kg, 0. 15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 1.25 mg / kg, or 1.5 mg / kg.

[0479] Embodiment 36A provides the method of any one of embodiments 29A-35A, wherein the subject is administered about 1 to about 1000 mg of the AARA.

[0480] Embodiment 37 A provides the method of any one of embodiments 29A-36A, wherein the subject is administered about 1 to about 1000 mg of the psychedelic agent.

[0481] Embodiment 38A provides the method of any one of embodiments 29A-37A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as separate dosage forms.

[0482] Embodiment 39A provides the method of any one of embodiments 29A-38A, wherein the pharmaceutical composition comprising the AARA is administered to the subject about 1 minute to about 24 hours before the pharmaceutical composition comprising the psychedelic agent is administered to the subject.

[0483] Embodiment 40 A provides the method of any one of embodiments 29A-39A, wherein the pharmaceutical composition comprising the AARA is administered to the subject.

[0484] Embodiment 41 A provides the method of any one of embodiments 29A-40A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are administered concurrently. Atorney Docket No. 047162-7542WOl(02749)

[0485] Embodiment 42 A provides the method of any one of embodiments 29A-41A. wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

[0486] Embodiment 43A provides the method of any one of embodiments 29A-42A, wherein the single dosage form comprises an anti-abuse formulation.

[0487] Embodiment 44A provides the method of any one of embodiments 29A-43A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are independently administered by a route independently selected from the group consisting of oral transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonaiy, intraduodenal, intragastrical. intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0488] Embodiment 45A provides the method of any one of embodiments 29A-44A, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent each independently further comprise at least one pharmaceutically acceptable earner or excipient.

[0489] Embodiment 46 A provides a method of treating, ameliorating, and / or preventing post- traumatic stress disorder in a human subject in need thereof, the method comprising: administering to the human subject: i) a pharmaceutical composition comprising a a.2A-adrenergic receptor agonist

[0490] (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a pharmaceutical composition comprising a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA is administered (i) more than 24 hours before administration of the pharmaceutical composition comprising the psychedelic agent or (ii) about 20 minutes or about 45 minutes before administration of the pharmaceutical composition comprising the psychedelic agent; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

[0491] Embodiment 47A provides the method of embodiment 46A, wherein Atorney Docket No. 047162-7542WOl(02749) i) the pharmaceutical composition a c -adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 20 mg / kg of the AARA; and ii) the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of 0.0001 mg / kg to 0.9 mg / kg or 1. 1 mg / kg to 5 mg / kg of the psychedelic agent.

[0492] Embodiment 48A provides the method of any one of embodiments 46A-47A, wherein the AARA is guanfacine and the psychedelic agent is psilocybin.

[0493] Embodiment 49A provides a pharmaceutical composition comprising: i) a dose of 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 20 mg / kg of a a2 \-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and ii) a dose of 0.0001 mg / kg to 0.9 mg / kg or 1.1 mg / kg to 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

[0494] Embodiment 50A provides the pharmaceutical composition of embodiment 49 A, wherein the AARA is guanfacine and the dose of guanfacine is 0.005 mg / kg to 0. 10 mg / kg or 0.2 mg / kg to 1 mg / kg.

[0495] Embodiment 51 AA provides the pharmaceutical composition of any one of embodiments 49A-50A, wherein the dose of guanfacine is 0.005 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg. 0.5 mg / kg. 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg, 0.85 mg / kg, 0.9 mg / kg, 0.95 mg / kg, or 1 mg / kg.

[0496] Embodiment 52A provides the pharmaceutical composition of any one of embodiments 49A-51A, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is 0.01 mg / kg to 0.9 mg / kg or 1.1 mg / kg to 1.5 mg / kg.

[0497] Embodiment 53A provides the pharmaceutical composition of any one of embodiments 49A-52A, wherein the dose of the psilocybin is 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.35 mg / kg, 0.4 mg / kg, 0.45 mg / kg, 0.5 mg / kg, 0.55 mg / kg, 0.6 mg / kg, 0.65 mg / kg, 0.7 mg / kg, 0.75 mg / kg, 0.8 mg / kg. 0.85 mg / kg, 0.9 mg / kg, 1.25 mg / kg, or 1.5 mg / kg. Attorney Docket No. 047162-7542WOl(02749)

[0498] The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims

1. Attorney Docket No. 047162-7542WOl(02749)CLAIMSWhat is claimed is:

1. A method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a subject in need thereof, the method comprising: administering to the subject: iii) a pharmaceutical composition comprising a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and iv) a pharmaceutical composition comprising a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form or as separate dosage forms; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

2. The method of claim 1, wherein the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, methylnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

3. The method of claim 1, wherein the psychedelic agent comprises psilocybin, 2C-B (4- bromo-2,5-dimethoxyphenethylamine), ketamine, tryptamine, a tryptamine derivative, DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-dimethyltryptamine). 5-MeO-MiPT (5- methoxy-N-methyl-N-isopropyltryptamine), LSA (d-lysergic acid amide), LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

4. The method of claim 1, wherein the AARA is guanfacine and the dose of guanfacine is about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 1 mg / kg.Attorney Docket No. 047162-7542WOl(02749)5. The method of claim 4, wherein the dose of guanfacine is about 0.005 mg / kg, about 0.01 mg / kg, about 0.02 mg / kg, about 0.025 mg / kg, about 0.03 mg / kg, about 0.035 mg / kg, about 0.04 mg / kg, about 0.045 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg.

6. The method of claim 1, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg.

7. The method of claim 6, wherein the dose of the psilocybin is about 0.01 mg / kg, about 0.05 mg / kg, about 0. 1 mg / kg, about 0. 15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 1.25 mg / kg, or about 1.5 mg / kg.

8. The method of claim 1, wherein the subject is administered about 1 to about 1000 mg of the AARA.

9. The method of claim 1, wherein the subject is administered about 1 to about 1000 mg of the psychedelic agent.

10. The method of claim 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as separate dosage forms.

11. The method of claim 10, wherein the pharmaceutical composition comprising the AARA is administered to the subject about 1 minute to about 24 hours before the pharmaceutical composition comprising the psychedelic agent is administered to the subject.

12. The method of claim 1, wherein the pharmaceutical composition comprising the AARA is administered to the subject separately and / or at a different time from the pharmaceutical composition comprising the psychedelic agent.

13. The method of claim 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are administered concurrently.Attorney Docket No. 047162-7542WOl(02749)14. The method of claim 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

15. The method of claim 1, wherein the single dosage form comprises an anti-abuse formulation.

16. The method of claim 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are independently administered by a route independently selected from the group consisting of transdermal, transmucosal, (intra)nasal and (trans)rectal, intravesical, intrapulmonary. intraduodenal, intragastrical. intrathecal, subcutaneous, intramuscular, intradermal, intraarterial, intravenous, intrabronchial, inhalational, and topical administration.

17. The method of claim 1, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent each independently further comprise at least one pharmaceutically acceptable carrier or excipient.

18. A method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a human subject in need thereof, the method comprising: administering to the human subject: iii) a pharmaceutical composition comprising a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof and iv) a pharmaceutical composition comprising a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof wherein the pharmaceutical composition comprising the AARA is administered (i) more than 24 hours before administration of the pharmaceutical composition comprising the psychedelic agent or (ii) about 20 minutes or about 45 minutes before administration of the pharmaceutical composition comprising the psychedelic agent; and wherein the post-traumatic stress disorder in the subject is treated, ameliorated, or prevented.

19. The method of claim 18, whereinAttorney Docket No. 047162-7542WOl(02749) iii) the pharmaceutical composition a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of the AARA; and iv) the pharmaceutical composition comprising the psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof comprises a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of the psychedelic agent.

20. The method of claim 18 or 19, wherein the AARA is guanfacine and the psychedelic agent is psilocybin.

21. A pharmaceutical composition comprising: iii) a dose of about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 20 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and iv) a dose of about 0.0001 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 5 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

22. The pharmaceutical composition of claim 21, wherein the AARA is guanfacine and the dose of guanfacine is about 0.005 mg / kg to about 0. 10 mg / kg or about 0.2 mg / kg to about 1 mg / kg.

23. The pharmaceutical composition of claim 22, wherein the dose of guanfacine is about 0.005 mg / kg. about 0.01 mg / kg, about 0.02 mg / kg, about 0.025 mg / kg, about 0.03 mg / kg, about 0.035 mg / kg, about 0.04 mg / kg. about 0.045 mg / kg, about 0.05 mg / kg. about 0. 1 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.3 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, or about 1 mg / kg.

24. The pharmaceutical composition of any one of claims 21-23, wherein the psychedelic agent is psilocybin and the dose of the psilocybin is about 0.01 mg / kg to about 0.9 mg / kg or about 1.1 mg / kg to about 1.5 mg / kg.Attorney Docket No. 047162-7542WOl(02749)25. The pharmaceutical composition of claim 24, wherein the dose of the psilocybin is about 0.01 mg / kg, about 0.05 mg / kg, about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.35 mg / kg, about 0.4 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 1.25 mg / kg, or about 1.5 mg / kg.

26. A pharmaceutical composition comprising: iii) a dose of about 0.015 mg / kg, about 0.05 mg / kg or about 0.5 mg / kg of a a2A- adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and iv) a dose of about 1 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

27. A pharmaceutical composition comprising: iii) a dose of about 0. 15 mg / kg of a a2A-adrenergic receptor agonist (AARA), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof; and iv) a dose of about 0.3 mg / kg or about 3 mg / kg of a psychedelic agent or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

28. The pharmaceutical composition of claim 26 or 27, wherein the psychedelic agent comprises psilocybin, 2C-B (4-bromo-2,5-dimethoxyphenethylamine), ketamine, tryptamine, a tryptamine derivative, DMT (N.N-dimeth ltr ptamine). 5-MeO-DMT (5-methoxy- dimethyltryptamine), 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine), LSA (d- lysergic acid amide). LSD (lysergic acid diethylamide), or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.

29. The pharmaceutical composition of any one of claims 26-28, wherein the AARA comprises clonidine, dexmedetomidine, fadolimidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine. methyldopa, methylnorepinephrine, norepinephrine, detomidine, lofexidine, or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, or tautomer thereof.Attorney Docket No. 047162-7542WOl(02749)30. A method of treating, ameliorating, and / or preventing post-traumatic stress disorder in a subject in need thereof, the method comprising the pharmaceutical composition of any one of claims 21-29.

31. The method of any one of claims 1-3, 8-20, and 30, wherein the dose of the AARA is about 0.005 mg / kg to about 1 mg / kg.

32. The method of claim 31, wherein the dose of the AARA is about 0.01 mg / kg to about 0.1 mg / kg.

33. The method of any one of claims 1-3, 8-20, and 30, wherein the dose of the psychedelic agent is about 0.01 mg / kg to about 5 mg / kg.

34. The method of claim 33. wherein the dose of the psychedelic agent is about 0.1 mg / kg to about 1 mg / kg.

35. The method of any one of claims 1-9, 18-20, and 30-34, wherein the pharmaceutical composition comprising the AARA and the pharmaceutical composition comprising the psychedelic agent are formulated as a single dosage form.

36. The method of claim 35, wherein the single dosage form is a tablet or a capsule.

37. The method of claim 35 or 36, wherein the pharmaceutical composition comprising the AARA is formulated as an immediate release component.

38. The method of claim 35 or 36, wherein the pharmaceutical composition comprising the AARA is formulated as a delayed release component.

39. The method of any one of claims 35-38, wherein the pharmaceutical composition comprising the psychedelic agent is formulated as an immediate release component.

40. The method of any one of claims 35-38, wherein the pharmaceutical composition comprising the psychedelic agent is formulated as a delayed release component.

41. The method of any one of claims 1-20 and 30-40, wherein the AARA is guanfacine, wherein the psychedelic agent is psilocybin, and wherein the guanfacine and the psilocybin are the only therapeutically effective agents administered to the subject.

42. The pharmaceutical composition of any one of claims 21-29, wherein the AARA is guanfacine, wherein the psychedelic agent is psilocybin, and wherein the guanfacine and theAttorney Docket No. 047162-7542WOl(02749) psilocybin are the only therapeutically effective agents present in the pharmaceutical composition.

Images